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I. Zusammenfassung 
 
Das Ziel der vorliegenden Arbeit war die Entwicklung massenspektrometrischer Verfahren 
zur Gehaltsbestimmung von Wirkstoffen und Drogen in Körperflüssigkeiten. Im Besonderen 
wurden dabei neue Technologien für die Aufreinigung und Trennung der Analyten untersucht 
und Vorteile zu konventionellen Methoden aufgezeigt.  
Als Beispiele dienten drei Substanzen und deren Metaboliten sowie strukturähnliche 
Substanzen: Acetaminophen, ein weit verbreitetes Analgetikum, und zwei Herzglykoside, 
Digoxin und Digitoxin. Zwei Hochleistungsflüssigkeitschromatographie-Tandem-
Massenspektrometrie Methoden basierend auf konventionellen Probenvorbereitungs- und 
Trennmethoden wurden entwickelt, welche die Quantifizierung aus Serum und Plasma 
ermöglichten. Nach erfolgreicher Validierung dieser Methoden erfolgte ein Vergleich mit 
anderen Laboratorien basierend auf Patientenkollektiven.  
In einem nächsten Schritt wurde die mögliche Beschleunigung und Automatisierung der 
Messsysteme untersucht. Eine Aufarbeitung mit magnetischen Mikropartikeln ist eine 
schnelle und automatisierbare Alternative für die Extraktion von Serumproben, wie am 
Beispiel des Acetaminophens bewiesen werden konnte. Das Potential der 
Ionenmobilitätstrennung konnte beispielhaft für Digitoxin und drei seiner Metabolite 
demonstriert werden. Dazu wurde eine differentielle Mobilitätsspektrometrie Methode ohne 
chromatographische Trennung entwickelt, die eine zehnfache Beschleunigung der Messung 
bei gleichbleibender Leistung erlaubte. 
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II. Abstract 
 
The aim of this dissertation was the development of mass spectrometric assays for the 
quantitation of therapeutic drugs and drugs of abuse in body fluids. New purification and 
separation techniques were used and their benefit on the performance of the assay was shown 
in comparison to established sample preparation and separation methods.  
Three representative pharmacologically active substances, including their metabolites and 
structurally similar compounds were chosen for this study: acetaminophen, a common 
analgesic and antipyruvic drug, and two cardiac glycosides, namely digoxin and digitoxin. 
Two LC-MS/MS methods were established for the quantitation of these analytes in serum 
and plasma. Both assays were validated and results for patient samples were compared to 
other laboratories for the main target substances.  
In a next step, analysis time reductions and automation of the analysis using new purification 
and separation technologies was investigated. An alternative sample preparation method 
using magnetic microparticles as extraction support was established for acetaminophen, 
which allowed specific and automated extraction of the target substances. The potential of 
differential ion mobility spectrometry (DMS) as an alternative separation method in 
comparison to high performance liquid chromatography was shown by means of digitoxin 
and three metabolites. This assay allowed a 10-fold speed increase while maintaining similar 
performance as compared to the conventional LC-MS/MS assay.  
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III. Abbreviations 
APAP   N-acetyl-p-aminophenol  
CCS   collision cross section 
DG   digoxin 
DAT   drugs of abuse testing 
DMS   differential ion mobility spectrometry 
DoE   design of experiment 
DRUID   Driving Under the Influence of Drugs 
DT   digitoxin 
hcPS   hyper-crosslinked polystyrene 
HPLC   high performance liquid chromatography 
IMS   ion mobility spectrometry 
JCTLM  Joint Committee for Traceability in Laboratory Medicine 
LC-MS/MS  liquid chromatography-tandem mass spectrometry 
LLE   liquid-liquid extraction 
ng/mL   nanograms per milliliter 
PFP   pentafluorphenyl 
pg/mL   picograms per milliliter  
ROSITA   Roadside Testing Assessment 
SLE   supported liquid extraction 
SPE   solid phase extraction 
TDM   therapeutic drug monitoring 
µg/mL   micrograms per milliliter 
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IV. Introduction 
 
Drug of abuse testing (DAT) and therapeutic drug monitoring (TDM) have the common 
requirement of needing fast and accurate methods to identify and quantify pharmacologically 
active substances and their metabolites in body fluids. [1, 2] Significant progress has been 
made in the discovery and synthesis of new drugs for therapeutic as well as for abusive use. 
[3, 4] TDM is needed to ensure correct dosing and to achieve a therapeutic level with 
minimized unwanted or sometimes even life-threatening side-effects. [5-8] In the DAT field, 
analytical methods are required to identify quickly what substance the tested person is under 
the influence of, and at what concentration level. [2, 9] In both cases, analytical tools used to 
assess these problems have to be able to quickly adapt to the broad panel of new drugs 
available on the market.  
Most methods described for these applications are based on spectrophotometry or 
immunoassays. Their lack of specificity has led to the rise of mass spectrometric methods, 
which provide fast, versatile and economic alternatives. Compared to immunoassays, liquid 
chromatography coupled to tandem mass spectrometry (LC-MS/MS) offers the additional 
possibility of analyte multiplexing. [10-12] Many pharmacologically active substances are 
quickly metabolized after intake and are often not detectable in their native form in body 
fluids. Known metabolites and degradation products can be included in LC-MS/MS assays, in 
addition to the native substance. [13] Additionally, LC-MS/MS offers the possibility of 
metabolite profiling. [14, 15] Before application for clinical use with patient samples, assays are 
subject to validation including at least the assessment of sensitivity, trueness and precision, to 
ensure that the reported results will be safe to use for medical decisions. [16] This is 
particularly important for drugs with narrow therapeutic windows, e.g. aminoglycosides, 
which can cause nephrotoxicity or ototoxicity when dosed in wrong concentrations. [17] 
Most DAT and TDM assays use serum, plasma or urine as sample matrix. Because of the 
growing need for simple, fast and non-invasive sample collection methods for which no 
medical personnel is required, new methods are developed based on alternative sample 
matrices (e.g. oral fluid, hair, sweat, exhaled breath etc.). [9, 18-24] These methods are useful in 
the context of programs such as DRUID (Driving Under the Influence of Drugs) [25] or 
ROSITA (RoadSIde Testing Assessment),[26] but they are prone to problems such as low 
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analyte concentration, inhomogeneity and possible false-positive results by exposure to food, 
tobacco or cosmetic products. [21] Improvement of these assays is therefore necessary to reach 
the reliability of results obtained from conventional matrices such as serum or plasma. 
LC-MS/MS assays comprise a sample preparation step to purify the target analyte(s) and a 
separation step via chromatography to separate analytes from residual matrix components 
before mass spectrometric detection. The goal of this thesis was to investigate the possibility 
of a generic LC-MS/MS system for analysis of various types of analytes in the DAT/TDM 
field. For this work, a high pressure liquid chromatography (HPLC) system with a reversed 
phase chromatography column (pentafluorphenyl (PFP) phase) was used, which allowed the 
separation of analytes with a broad range of chemical properties. It was hyphenated to a triple 
quadrupole mass spectrometer, facilitating high sensitive detection. Special attention was 
paid towards optimization of the sample preparation procedure, speed-up and possible 
automation of the workflow. 
Many sample preparation techniques have been established and allow thorough clean-up of 
samples in complex matrices such as body fluids. Depending on the nature of the target 
analyte(s), methods such as protein precipitation, solid phase extraction (SPE) [27-30] and 
liquid-liquid extraction (LLE) [31-33] are available to specifically extract one or a combination 
of target substances from interfering matrix components such as high-abundant proteins, 
phospholipids, salts etc. However, optimization of these techniques for specific applications 
is often time-consuming, frequently involves multiple steps and requires large sample 
volumes to achieve sensitive analysis. Also, sample throughput is limited by steps which are 
performed in batch mode and therefore cause long turnaround times, e.g. centrifugation. [34] 
Another drawback complicating the use of LC-MS/MS as a routine analysis tool is the high 
costs of the assays. Consumables needed for sample extraction are relatively expensive and 
well-trained scientists have to operate the system and perform tedious data analysis 
procedures. These limitations underpin the need for automated, fast and cost-efficient sample 
analysis methods. 
Coated magnetic microparticles have shown high potential as extraction media for sample 
preparation. [35] Particle suspensions can be handled as liquids, allowing full automation and 
speed-up of the sample preparation process. Smaller sample volumes can be handled 
compared to conventional SPE methods due to the high specific surface of the beads. This 
offers the advantage of either a lower consumption of sample volumes or a higher 
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concentration of the eluate prior to LC-MS/MS analysis. Several applications have been 
reported, where either analytes are extracted from a complex matrix or where the matrix 
components were removed from the sample, leaving a clean extract. [36-38] Magnetic beads 
have low synthesis costs and produce less waste compared to SPE workflows. A broad range 
of chemical surface modifications are available for magnetic beads, allowing very specific 
(e.g. MIP, antibody-/aptamer-coating) as well as unspecific extraction mechanisms (reversed 
phase, ion exchange etc.). Thus they can be adapted to many applications including not only 
DAT/TDM analyses but also proteomics, steroids, hormones and waste water analysis. 
Another approach to improve sample throughput is to focus on the optimization of analyte 
separation after sample clean-up. Major progress has been made in the last years for the 
development of faster chromatographic systems without compromising separation power. [39, 
40] New column materials and HPLC systems are available, which considerably reduce 
separation times for large collectives of target substances. Other techniques are available to 
further enhance separation times of complex mixtures of analytes, such as ion mobility 
spectrometry (IMS). [41] In IMS, ions are directed through a cell filled with an inert gas and 
are separated based on their difference in mobility in the gas phase by applying an external 
electrical field. Multiple instrument configurations exist for IMS, e.g. differential ion 
mobility spectrometry (DMS). When included in an LC-MS assay, DMS can either act as a 
filter prior to MS detection reduce background noise or it can be used as a third dimension of 
separation to improve the specificity of the assay. [42] This approach has shown great potential 
for the separation of isobaric compounds (metabolites, endogenous substances etc.) [43, 44] that 
can hardly be differentiated by conventional chromatography. DMS separation can be 
improved by adding ion pairing reagents to analyte mixtures. [45-49] Migration behavior of 
analyte clusters in the DMS cell can be predicted using adequate modeling software tools. [50, 
51] 
Conventional methods of drug testing using LC-MS/MS already play an increasingly 
important role in clinical and forensic laboratories. Further developments in technology are 
needed to allow generic routine measurement of analytes in clinical laboratories and support 
the implementation of new therapeutic drugs and detection of narcotics in the future. The 
objective of this study was to demonstrate the possibility of a generic LC-MS/MS based 
system for fast, versatile and automatable quantitation of pharmacologically active substances 
in complex biofluids. The experimental strategy was first to establish conventional 
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quantication methods for three representative analytes and their metabolites as test systems. 
Then, detailed investigation of new purification (magnetic bead based sample preparation) 
and separation technologies (DMS) was planned in terms of reduction of both analysis time 
and manual handling.  
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V. Summary and Conclusions  
Three representative analytes were exemplary chosen for development of the new 
instrumental platform described in this work: acetaminophen, a widely used over-the-counter 
analgetic and antipyruvic drug which is mainly metabolized in the liver and can cause severe 
liver damage in case of an overdose, and digoxin and digitoxin, two cardiac glycosides with a 
very narrow therapeutic range. Detailed descriptions of this work can be found in the 
publications listed in chapter VII. 
1. Acetaminophen  
In a first part, an LC-MS/MS assay was developed to quantify acetaminophen (N-acetyl-p-
aminophenol, APAP), four of its metabolites (acetaminophen-glucuronide, acetaminophen-
sulfate, acetaminophen-mercapturate and acetaminophen-cysteine), its antidote (N-
acetylcysteine) and four additional compounds (phenacetin, phenetidine, imipramine and 
amitriptyline) known to cross-react with the immunoassay-based acetaminophen test in 
human serum and plasma. Because of the high concentration levels expected for these 
analytes in serum (up to 200 µg/mL), a simple protein reduction and filtration step was 
sufficient to allow quantitation of all target compounds in the desired concentration range. 
Chromatographic separation was performed on a PFP separation column. Analytes were 
detected using a triple quadrupole mass spectrometer. This method was validated and showed 
good performance in terms of accuracy, precision and linearity. Method comparison was 
carried out by means of data from a routine laboratory using 77 patient and spiked samples 
and showed good correlation. Our assay has been accepted and listed as a certified reference 
method by the Joint Committee for Traceability in Laboratory medicine (JCTLM).[52]  
In a second stage of the project, an alternative sample preparation method based on extraction 
using magnetic microparticles was developed for the analyte combination described above. 
Because of the large number of parameters suspected to have an influence on the extraction 
process, experiments were thoroughly planned using design of experiment (DoE). Several 
bead types were screened and one suitable type was found that allowed simultaneous 
extraction of the target substances with a very broad range of polarities directly from serum. 
The resulting assay was validated and compared to the developed reference method using 68 
native patient samples. It was shown that the correlation between both methods was 
excellent, further underpinning the good performance of the assay using magnetic beads in 
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terms of accuracy. Analysis time was reduced by a factor of 4 while maintaining the same 
imprecision as the reference method (CV 2-4% for APAP and 2-9% for metabolites); further 
time reductions can even be achieved by using an automated liquid handling system in the 96 
well-plate format. The magnetic bead based method was fast, simple and could be readily 
applied to simultaneous extraction of analytes with a wide range of chemical polarities. 
Extension of the method to other target substances should be readily possible.  
2. Digoxin/Digitoxin 
The next part of the thesis focused on the quantitation of two cardiac glycosides: digoxin 
(DG) and digitoxin (DT). Contrary to acetaminophen, the concentration levels of these drugs 
in human serum were much lower, only a few nanograms per milliliter (ng/mL), making the 
availability of a very sensitive analysis system crucial for quantitation. The developed assay 
was targeted towards digoxin, digitoxin and eleven of their metabolites (digoxin-bis-
digitoxose, digoxin-mono-digitoxose, digitoxin-bis-digitoxose, digitoxin-mono-digitoxose, 
digoxigenin, digitoxigenin, dihydrodigoxin, acetyl- and methyldigoxin, deslanoside and 
lanatoside). Because of the different chemical properties of the target substances and their 
very low concentration levels, extensive sample preparation had to be performed before LC-
MS/MS analysis. A combination of protein precipitation and supported liquid extraction 
(SLE) was necessary to reach the needed sensitivity of the assay. Chromatographic separation 
and MS detection were performed on the same platform described previously for 
acetaminophen. The assay was validated; trueness was verified for the two main analytes by 
analyzing 29 spiked and native samples for DG and 8 native samples for DT and comparing 
the results to established reference methods for DG and DT. 
In a next step, the potential benefit of differential ion mobility spectrometry (DMS) as a 
potential replacement for chromatographic separation was investigated using DT and three of 
its metabolites. The influence of chemical modifiers and ionic additives on the separation 
potential of the DMS cell was investigated and showed that it only improved slightly with 
gas-phase modifiers. The decisive factor was shown to be cluster formation of the analytes 
with alkali ions. Separation efficiency increased with increasing size of the counter ion, 
yielding the optimum results with cesium. It was demonstrated that DMS on its own could be 
used for separation of analyte mixtures. Using a ballistic chromatographic approach, serum 
samples could be quantified by DMS-MS/MS in less than 1.5 min, which allowed a speed-up 
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of the analysis of factor 10 by maintaining the same imprecision of 2-13% compared to the 
previously described method. 
3. Outlook 
The work described in this thesis represents a significant step towards establishment of a 
generic system for quantitation of various drugs and their metabolites in body fluids using 
LC-MS/MS. The developed mass spectrometry techniques have proven to be a very useful 
approach to solving the studied analytical problems due to their versatility, specificity and 
fast method development time as compared to immunoassay-based tests. Nevertheless, as 
described before, several limitations were encountered and needed to be assessed before 
implementation of LC-MS/MS as routine analysis tool.  
In our experiments, the evaluated technologies showed promising results and proved to be 
applicable to a large number of different analytes exhibiting a broad range of polarities in 
different concentration ranges. A workflow combining sample extraction with magnetic 
beads and detection by DMS-MS/MS allowed a significant reduction of analysis time, full 
automation of the process and considerable decrease of cost per result, while maintaining the 
analytical performance of assays based on established techniques.   
These results will undoubtedly support implementation of LC-MS/MS as a routine tool for 
DAT/TDM applications in clinical laboratories in the future. However, several issues still 
need to be assessed before this can be fully realized. Firstly, the robustness of the system 
needs to be further improved to the point where random access analysis of various targets is 
possible and frequent hardware maintenance is not required anymore. Furthermore, new 
calibration concepts should be implemented, to enable weekly instead of daily calibration of 
the system. Finally, user interaction time could be further minimized if adequate software 
tools were available for automated and reliable data interpretation.   
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Recent advances in sample preparation techniques
to overcome diﬃculties encountered during
quantitative analysis of small molecules from
bioﬂuids using LC-MS/MS
Caroline Bylda,ab Roland Thiele,a Uwe Kobolda and Dietrich A. Volmer*b
Liquid chromatography-mass spectrometry analysis of small molecules from bioﬂuids requires sensitive
and robust assays. Because of the very complex nature of many biological samples, eﬃcient sample
preparation protocols to remove unwanted components and to selectively extract the compounds of
interest are an essential part of almost every bioanalytical workﬂow. This review describes the most
common problems encountered during sample preparation, ways to optimize established sample
preparation techniques and important recent developments to reduce or eliminate major interferents
from bioﬂuids.
Introduction
The primary goal of sample preparation is to isolate one or
several target analytes from the other components of the sample
mixture (matrix). Depending on their nature and concentration
levels, co-components of the sample matrix can inuence the
quantitation of target analyte(s) during subsequent liquid
chromatography-mass spectrometry (LC-MS) or tandem mass
spectrometry (LC-MS/MS) experiments if not removed prior to
analysis. The development of new LC-MS/MS methods for small
molecules in biological uids is becoming increasingly more
challenging, because of the need to continuously achieve higher
sensitivity and better assay robustness in complex biouids
such as serum, plasma, urine, oral uid or cerebrospinal uid
(CSF). In addition, because of the very low concentration levels
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of pharmaceutical targets, samples oen need to be pre-
concentrated before analysis. Unfortunately, this does not only
increase the concentration of the desired compound in the
sample extract but also oen raises the levels of interfering
components. As a result, very specic and eﬀective sample
clean-up procedures are required for sensitive and selective LC-
MS/MS assays today.1
This short review presents the main diﬃculties encountered
during sample preparation for analysis of small molecules from
biouids by LC-MS/MS and summarizes several critical factors
that particular attention should be paid to, followed by an
overview of the latest developments in sample preparation
techniques to overcome common diﬃculties with complex
biouids.
Matrix eﬀects
The general term used today to describe problems encountered
during analysis of complex biological samples is “matrix
eﬀects”. These eﬀects are usually caused by endogenous (e.g.
metabolites of the target analyte, proteins or lipids) or exoge-
nous (all substances introduced during sample processing and
analysis) compounds. Depending on their chemical properties,
it may or may not be necessary to remove all of these interfer-
ents from the sample before injection into the LC-MS system.
Also, only matrix compounds coeluting with target analytes
during the chromatographic separation prior to MS analysis can
cause a change in the response of the analyte, either positive
(ion enhancement eﬀect) or negative (ion suppression eﬀect).2
Diﬀerent methods have been presented to examine matrix
eﬀects. A common approach is the post-extraction spike
method,3–5 where the peak area of the target analyte that has
been spiked into the biological matrix prior to the sample
preparation is compared to the area of the same analyte spiked
post-extraction into the biological uid extract. The ratio
between the two values represents the absolute matrix eﬀect.
The relative matrix eﬀect is determined by comparing several
lots of the biological matrix.3 Obviously, both absolute and
relative matrix eﬀects depend strongly on the target analyte and
the ionization technique used for LC-MS/MS.
Another popular method is post-column infusion,6–8 where
possible matrix eﬀects are assessed by continuous post-column
infusion of the analyte aer injection of a processed blank
serum sample onto the chromatography column. Any variation
of signal intensity at or near the retention times of the analyte
would indicate the presence of substances from the matrix
interfering with the analysis.
Matrix eﬀects have been shown to be dependent on the
ionization methods used for the LC-MS method,3 which are
usually either electrospray ionization (ESI) or atmospheric
pressure chemical ionization (APCI) in most modern LC-MS/MS
assays. The chemical structures and the concentration levels of
both analyte and co-eluting mixture components determine
whether they outcompete each other during the ionization
process.9 For example, ESI is particularly sensitive to co-eluting
phospholipids because ESI is strongly biased towards surfac-
tants,10 which enrich at the surface of the droplets during the
liquid/gas-phase ion transfer. That is, phospholipids at the
surface of droplets can inhibit ejection of analyte ions trapped
inside the droplets. On the other hand, APCI is oen less
aﬀected by suppression eﬀects, as there is no competition
between compounds to enter the gas-phase of the mass spec-
trometer. Nevertheless, APCI still experiences matrix eﬀects in
multicomponent samples. As biouids contain numerous
endogenous molecules, oen at high levels, with potentially
very high basicities and surface activities, ion suppression
eﬀects will almost always be present in any LC-MS/MS assay.
Diﬀerent strategies are available to eliminate or reduce
matrix eﬀects. One approach is to optimize the chromato-
graphic separation to separate the analytes from interfering
compounds.1,11,12 This can, however, result in long chromato-
graphic run times. Another approach is to optimize the sample
preparation, to obtain clean extracts of the target analytes. With
proper sample preparation and the use of isotopically labeled
standards, many matrix eﬀects can be eliminated or strongly
reduced. Some cases remain, however, where the high vari-
ability of the matrix composition makes the use of standard
addition calibration necessary.13–16
There are several well-known causes for matrix eﬀects in the
analysis of clinically-relevant substances from biological
samples. For example, hemolyzed or lipaemic samples have
great inuence on the analysis of serum and plasma
samples.17,18 Cases also have been reported, where buﬀers used
for solid-phase extraction (SPE) triggered matrix eﬀects in
LC-MS/MS.19 The most important interferents, however, are
phospholipids, which not only aﬀect MS response of many
analytes greatly, but which are also very diﬃcult to remove from
the samples.
Phospholipids
Phospholipids (PPL) are major constituents of cell membranes
and are therefore very abundant in serum and plasma.20 They
consist of two functional groups: a hydrophilic head group
composed of phosphate and choline units, and a hydrophobic
tail, made up of fatty acyl chains. The most abundant phos-
pholipids are glycerophosphocholines (GPChos) (70% of total
phospholipids) and lysophosphatidylcholines (10% of total
phospholipids) (Fig. 1).11 These two groups are known to cause
serious ion suppression eﬀects in LC-MS analysis, caused by
competition for space on the surface of droplets formed during
Fig. 1 Chemical structures of the two most important groups of
phospholipids.
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the ESI process (vide supra).3,10 Phospholipids are present at
diﬀerent concentration levels in serum and plasma samples,
depending on the sampling device used.21 A very simple method
to monitor possible ion suppression eﬀects from GPCho was
described by Little et al. as in-source multiple reaction moni-
toring (IS-MRM).22 Using the positive ion mode, a common
product ion for the most abundant GPCho is trimethylammo-
nium-ethyl phosphate at m/z 184, which was monitored during
analysis of an analyte-free sample. This class-specic product
ion was generated using in-source dissociation of the eluting
GPCho during the chromatographic run.22 Other methods have
been described that allow screening for less abundant phos-
pholipids by adding a precursor ion in the negative mode or by
using positive ion neutral loss scans.23
Studies have shown that the use of methanol as a mobile
phase for chromatographic separation provided signicant
advantages over acetonitrile, because elution of all GPCho
occurred in a very narrow time window and their retention
behavior on reversed-phase columns could be predicted and
decreased by increasing the percentage of the organic phase.24
The PPL tended to elute at a high content of the organic mobile
phase25 and were completely removed from the system at the
end of a run by ushing the analytical column with iso-
propanol.26
The behavior of PPL has also been investigated on hydro-
phobic interaction liquid chromatography (HILIC) columns:27
the compounds were focused into 2 groups of peaks (phos-
phatidyl cholines and lyso-phosphatidyl cholines) and eluted
completely from the column in a one gradient cycle. In
comparison, on a reversed-phase material, a strong carry-over
was observed from one gradient cycle to another.27
In some cases, where retention times of target analytes and
PPL overlapped, elution of the target substance could be shied
aer adding mobile phase modiers.27
Internal standards
The use of isotope-labeled internal standards can help over-
come most of the matrix eﬀects during sample preparation and
LC-MS/MS analysis. However, in some cases the internal stan-
dard cannot completely fulll its purpose, because of slight
diﬀerences in the chemical behavior of the target analyte and
internal standard. For example, particular attention has to be
paid to analytes showing strong protein binding.28 Generally it
is necessary to allow enough time for the internal standard to
properly equilibrate and bind to the protein before extraction,
to ensure identical behavior of the internal standard and target
analyte.29 A method has been described to determine the extent
of protein binding of corticosteroids.30 In theory, this method
could be extended to other substances and be used to compare
the protein-aﬃnity of an analyte and its internal standard. It is
important that the release of analytes from the protein (e.g. by
adding organic solvents for protein precipitation, o-phosphoric
acid for breakdown of non-covalent intermolecular interac-
tions31 or dithiothreitol (DTT) or tris(2-carboxyethyl)phosphine
(TCEP) for reduction of disulde bonds) has the same impact
on the analyte and isotope-labeled standard. A case was
reported, where the higher susceptibility of the internal stan-
dard for matrix eﬀects than the target analyte led to an under-
estimation of up to 50% in the presence of specic buﬀers used
for SPE sample preparation (Fig. 2).19
Generally, 13C, 15N or 18O-labeled internal standards are
preferable to deuterium labeled analogs,32 because slight
diﬀerences of physicochemical properties between hydrogen
and deuterium can result in small shis of retention times of
the analyte and internal standard. In some cases, this has led to
a diﬀerent degree of ion suppression for the analyte and the
internal standard, resulting in changed analyte/internal stan-
dard peak area ratios.33,34 Also, deuterium–hydrogen back-
exchange can occur, which has led to false positive results.35
Unfortunately, in many cases only deuterated compounds are
commercially available, which increases the need to carefully
investigate the stability of the reference standards and the
inuence of matrix eﬀects on the method.
Optimization of established sample
preparation methods
Even though there has been some recent interest in quantitative
analysis of pharmaceutical compounds from biological samples
using ambient, direct mass spectrometry techniques such as
desorption electrospray ionization (DESI) or direct analysis in
real time (DART), with little or no prior sample preparation or
chromatography,36 sample clean-up remains a critical step in
most LC-MS analyses of small molecules in biouids.
Protein precipitation
The simplest sample preparation approach for biouids is
protein removal. Proteins can be denatured using acids or heat,
or removed by using ultraltration cut-oﬀ membranes.37
Another possibility is to use organic solvents for protein
precipitation (PPT). PPT removes a part of the phospholipid
content present in serum and plasma samples, depending on
the organic solvent used. Studies have shown that methanol
extracts contain 40% more phospholipids compared to aceto-
nitrile,11 and are also less clean than tetrahydrofuran or ethanol
extracts.38
Solid-phase extraction (SPE)
Silica-based sorbents in SPE cartridges have excellent retention
capacity for PPL when eluted with 100% acetonitrile.39 Clean
extracts were also obtained by including a washing step with up
to 50%methanol, but this strongly aﬀected the recovery of polar
analytes.39 Large amounts of methanol eluted signicant
amounts of phospholipids from silica-based reversed-phase
SPE cartridges. Methanol contents of 60, 70 and 80% for elution
of samples on phenyl, C8 and C18 phases resulted in a high
concentration of phospholipids in the extracts. Acetonitrile
appeared to be a stronger eluent for phospholipids on reversed-
phase materials when present at levels up to 50%. The same
study showed that the recovery of lysophosphatidylcholines
decreased with the increasing content of acetonitrile (>50%),
reaching its minimum at a 100% organic phase.40 The retention
This journal is © The Royal Society of Chemistry 2014 Analyst
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of phospholipids on the sorbent increased by interactions with
residual silanol groups, as was shown by comparison of end-
capped and non-endcapped materials. Silica-based sorbents
were compared to polymeric phases regarding extraction of
phospholipids, and the tested materials showed comparable
eﬃciency.40
Studies comparing diﬀerent sample preparation methods in
terms of matrix eﬀects and analyte recovery demonstrated that
mixed-mode strong anion exchange SPE wasmore eﬀective than
PPT and LLE for polar and non-polar analytes in plasma
(Fig. 3).11,41
HILIC-SPE was evaluated as an eﬀective method to remove
phospholipids from serum and plasma samples.26 The reten-
tion of phospholipids was shown to increase when samples
were diluted with acetone. For some applications to urine
samples, HILIC materials were more eﬀective than reversed-
phase materials.42 The polar metabolites in urine had to be
separated from the salts and other polar components present in
urine. Orthogonal separation using both HILIC and reversed-
phase materials for sample preparation and chromatography
improved the eﬀectiveness of sample clean-up.42
Overall, SPE has a very broad range of applications in the LC-
MS/MS quantication of small molecules in biouids.43–47
Liquid–liquid extraction (LLE)
Liquid–liquid extraction has found numerous applications for
analysis of pharmaceuticals and their metabolites. The
concentration of residual phospholipids in the extract is usually
lower compared to other techniques such as mixed-mode SPE;
on the other hand, the extraction eﬃciency for highly polar
analytes is also lower.29 The choice of extraction solvent is very
important to reduce unspecic extraction of matrix compo-
nents.41 Halogenated solvents such as chloroform or dichloro-
methane48–50 are commonly used in combination with
hydrophilic solvents (e.g. alcohols) for extraction of polar
compounds; they also have high aﬃnity for lipids.38
As non-ionized analytes are more eﬃciently extracted by
organic solvents than charged species, particular attention has
to be paid to the pH of the sample prior to LLE. As a general
rule, the pH should be between pKa and (pKa  2) for acidic
analytes and between pKa and (pKa + 2) for basic analytes,51 to
increase the extraction recovery. This obviously applies only if
Fig. 2 Injection of extracted blank human plasma (+0.2 mL triethylamine, blue and red traces) with an overlay of the control sample (20 ng mL1,
grey and green traces) containing piperaquine (PQ) and internal standard (d6-PQ) during post-column infusion at 10 mL min
1 of PQ and d6-PQ
(1.2 ng mL1). Electrospray ionization of the analytes was performed in positive ion mode; the MRM transitions were m/z 535/ 288 and m/z
541/ 294 for PQ and D6-PQ, respectively (reprinted with permission from ref. 19).
Fig. 3 MRM traces for ﬁve residual phospholipids in rat plasma
extracts after sample preparation by (A) acetonitrile PPT, (B) reversed-
phase polymeric SPE, (C) silica-based pure cation exchange, and (D)
mixed-mode cation exchange SPE. The phospholipids monitored
were 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine (m/z
496.35), 1-stearoyl-2-hydroxy-sn-glycero-3-phosphocholine (m/z
524.37), 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-
phosphocholine (m/z 758.57), 1-(9Z,12Z-octadecadienoyl)-2-
(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphocholine (m/z
806.57) and a ﬁfth glycerophosphocholine lipid of molecular weight
703.57 Da. MRM analysis was performed on an ESI triple quadrupole
LC-MS/MS system using a methanol–water gradient at pH 10
(reprinted with permission from ref. 11).
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the stability of the main analyte and its potentially labile
metabolites is given in this pH range.29
Extraction using methyl-tert-butylether (MTBE) has shown
good results,52 but signicantly lower analyte recoveries were
seen compared to mixed mode SPE and PPT, especially for polar
analytes.11 Only traces of phospholipids were found in MTBE
and n-butylchloride extracts of serum and plasma samples.53
However, particular attention has to be paid to the process,
when several sample preparation steps are combined. The clean
extracts obtained with MTBE for untreated serum or plasma can
show a high recovery for phospholipids if the samples contain a
high percentage of acetonitrile, e.g. aer protein precipitation
(Fig. 4).53
Extraction time also plays an important role for the specic
extraction of target analytes compared to matrix components. A
study showed that a 5 min extraction time yielded a cleaner
extract and better recovery for the target compound than 20
min, indicating that matrix compounds diﬀuse slower into the
extraction solvent.52
To improve low recovery rates of LLE for strongly hydrophilic
compounds, extraction procedures using water miscible
solvents have been considered. Complex methods were repor-
ted in the past that use temperatures below 0 C to achieve
phase separation of serum samples and extraction solvent.54 A
more convenient way to achieve phase separation between an
aqueous sample and a water-miscible solvent is salt-assisted
liquid–liquid extraction (SALLE), where the polarity of the
aqueous phase is increased by adding high concentration of
salt, leading to phase separation.55 This approach has been used
for quantitation of pharmaceutical compounds from biouids
using LC56 or LC-MS/MS.57–59
Novel sample preparation methods
Many common interferents can be removed with conventional
sample preparation methods (e.g. protein precipitation, SPE,
and LLE), but optimization of these techniques for specic
applications is oen complex, time-consuming and frequently
involves multiple steps. Many common interferents can be
removed with conventional sample preparation methods (e.g.
protein precipitation, SPE, and LLE), but optimization of these
techniques for specic applications is oen complex, time-
consuming and frequently involves multiple steps. Moreover,
some challenges involving very small sample volumes and low
abundant analytes remain. If repeated analyses are required
from the same sample and if no further sampling is possible,
sample preparation sometimes has to be performed using a
sample volume as low as a few microliters. Similar diﬃculties
apply to assays for metabolites or biomarkers that are present at
very low concentration levels in human samples. Here, the
method must be able to pre-concentrate the target substance(s),
additionally to removing all other components of the matrix.
New developments for sample preparation methods are there-
fore oen directed towards simplication and possible auto-
mation, miniaturization and specicity enhancements of the
clean-up process. New developments for sample preparation
methods are therefore oen directed towards simplication
and possible automation, miniaturization and specicity
enhancements of the clean-up process. In the following, the
most promising recent developments are briey summarized.
Supported liquid extraction (SLE)
Even though LLE is mostly a very eﬀective sample preparation
method, it has limitations, in particular low sample
throughput. Several extractions are oen required to improve
analyte recovery, sample handling is labor-intensive and time-
consuming, and emulsions can form at the interface between
liquid layers. These limitations can be overcome by using sup-
ported liquid extraction (SLE), where aqueous samples are
adsorbed on a porous solid support material, e.g. diatomaceous
earth. Some studies have shown analyte recovery from SLE that
was comparable or higher than LLE.60
Fig. 4 Extraction of C16:0 lysophosphatidylcholine (C16:0 lyso-PC) from human plasma using liquid–liquid extraction with three diﬀerent
solvents at diﬀerent pH values. Comparison to solid-phase extraction and two commercial phospholipid removal sorbents (PR-plate 1 and PR-
plate 2). Lyso-PC was monitored using the following MRM transition: m/z 496/ 184 (reprinted with permission from ref. 53).
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SLE has been shown to eﬀectively remove the majority of
phospholipids when the extraction conditions were carefully
optimized.61 The eﬃciency of several extraction solvents was
also compared for SLE:7 ethyl acetate removed about 85%,
MTBE removed more than 99% of total phospholipids.
Dichloromethane removed 99.5% of the phospholipids when
used alone; its removal eﬃciency decreased to 95% when iso-
propanol was added. However, addition of water-soluble
solvents to the samples (e.g., acetonitrile or methanol) prior to
SLE extraction led to higher matrix eﬀects for some analytes.7
Isopropanol combined with dichloromethane also yielded low
concentrations of phospholipids in the extract.7
The SLE technique has been implemented in various LC-MS/
MS methods recently.62–67 It was particularly powerful for
normal phase separation systems, since the high percentage of
organic solvent in the eluate did not need to be evaporated prior
to injection into the LC-MS/MS system.68
Phospholipid removal plates
The use of hybrid precipitation/SPE plates for selective removal
of phospholipids and precipitated proteins has been increasing
over the past few years.4,38,69,70 Several types of these plates are
now commercially available, e.g. Hybrid SPE™ (Sigma Aldrich),
Ostro™ (Waters), Captiva™ ND (Agilent) and Phree™ (Phe-
nomenex). These plates have shown very eﬀective extractions of
phospholipids compared to PPT.71 For example, the Hybrid SPE
plate specically retains phospholipids by Lewis acid–base
interactions between zirconia ions – which are bonded to the
stationary phase – and the phosphate group of the phospho-
lipids. Acetonitrile with 1% formic acid is used as the precipi-
tation agent; formic acid has important inuence on the
recovery of the analytes.72 Hybrid SPE extracts have shown to
contain signicantly lower phospholipid concentrations as
compared to PPT.4 Ostro uses a combination of protein
precipitation and extraction on a C18 sorbent. Several applica-
tions using these products have been reported.73–75
Other approaches are also possible for removal of phos-
pholipids. A study showed that addition of a colloidal silica
suspension together with lanthanum chloride to plasma
samples resulted in a reproducible sample clean-up without
loss of the analyte of interest.76
Magnetic beads
Magnetic particles and nanoparticles (MNPs) are becoming
increasingly interesting for sample preparation. They have been
used for extraction and pre-concentration of drugs in complex
biological uids.77–79 They consist of a magnetic core (e.g. Fe3O4)
coated with a polymer material, to which specic functionalities
can be added (Fig. 5).80 Sample preparation steps are similar to
SPE (loading, washing and elution). The magnetic particles
suspended in solution can be handled as a liquid. Obviously,
the big advantage of magnetic beads is that aer sample
extraction, the beads are pulled to the tube wall, the superna-
tant is removed and the wall-bound beads washed with an
appropriate solvent. The loaded beads are then re-suspended.
The entire procedure is fast and simple, and complete auto-
mation is readily possible.
Several applications have been reported, where either ana-
lytes are selectively extracted from a complex matrix81–83 or
where the matrix components were removed from the sample,
leaving a clean extract behind that can be directly injected into
the LC-MS system.84 Using matrix-assisted laser desorption/
ionization (MALDI), the analytes can also be analyzed without
having to be eluted from the magnetic beads rst.85 The
possible modications on the surface of the magnetic beads are
similar to conventional SPE and involve hydrophobic coatings,
ion exchange functionalities, molecular imprinted polymers
(MIP),86 restricted access87 or aﬃnity materials.88 Magnetic
particles have also been coated with carbon nanotubes and used
to extract aromatic compounds.89
Turboow
Turboow extraction is usually carried out online before chro-
matographic separation and uses columns with large particle
sizes in conjunction with high ow rates.90 Samples can be
directly injected aer dilution; sometimes a protein precipita-
tion step is required before injection. The target analytes are
retained in the pores of the column, whereas matrix compo-
nents are ushed through and discarded directly to waste. The
analytes are then eluted from the trapping column using
organic solvents. This method has the advantage of fast and
generic method development but unfortunately it can also show
high carry-over eﬀects.91 A study reported that this technique
had no signicant impact on phospholipid removal from serum
and plasma samples, and still needed extensive chromato-
graphic separation aer clean-up to avoidmatrix eﬀects.92Other
groups reported successful applications for quantication of
various substances (drugs, steroids, phenolic compounds,
etc.)93–102 in human serum, urine and dried blood spots using
reversed-phase, ion exchange or mixed-mode materials.
Monolithic spin column extraction
Monolithic spin column extraction is a fast sample preparation
method that uses a spin column packed with octadecyl silane-
bondedmonolithic silica as the extraction device.103 The sample
is loaded onto the sorbent by centrifugation; the same proce-
dure is performed for washing and elution steps.104 This tech-
nique is fast and easy, requires only small amounts of solvents
and allows high sample throughput. Unfortunately, the method
can only be applied over a limited pH range because of possible
degradation of the monolithic silica phase.104 Several applica-
tions have been reported for quantication of various analytes
from human samples, using underivatized,105 C18,106–108 ion
exchange109 or mixed-mode phases (C–C18, TiO–C18, C18-ion
exchange).110–112
Microextraction by packed sorbent (MEPS)
This recent sample preparation technique is based on the
miniaturization of conventional SPE, using a gas-tight syringe
as extraction device. The method is designed for sample
volumes from 10 to 1000 mL and can be connected online to
Analyst This journal is © The Royal Society of Chemistry 2014
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LC-MS or GC-MS. Compared to conventional SPE, MEPS is easy
to use, faster and needs signicantly lower amounts of organic
solvents. Additionally, MEPS sorbents can be used for up to 100
extractions.113
Packing materials for MEPS are similar to sorbents used for
SPE. Essentially, any sorbent material and functionalization can
be applied. For example, silica-based materials (C2, C8,
C18),114–118 with additional ion exchange functionality119 or even
as mixed-mode materials,120 restricted access materials (RAM),
HILIC, carbon, polystyrene–divinylbenzene copolymers (PS–
DVB) or molecular imprinted polymers113,121 have been utilized
for MEPS.
The method has been implemented in several recent reports
for quantication of pharmaceutical compounds from human
biological samples (urine, plasma, oral uid and whole blood),
including antipsychotic drugs,119 cardiac drugs,114 local anes-
thetics,115,121 phenolic acid,116 immunosuppressants,117
opioids120 and antidepressants.118 Recent studies have also
reported the successful extraction of trazodone from plasma
with polymer nano-bers as the extraction sorbent.122
Carbon nanotubes
Carbon surfaces have the ability to retain substances by strong
hydrophobic interactions. These materials are therefore inter-
esting for reversed-phase extractions of hydrophilic substances.
Carbon nanotubes (CNTs) are hollow cylinders that consist of
one (single-wall carbon nanotubes, SWCNTs) or several (multi-
walled carbon nanotubes, MWCNTs) graphene layers.123
Because of their large surface areas, CNTs have a high adsorp-
tion capacity. They show high aﬃnity towards aromatic
compounds that can be adsorbed via p–p interactions.124 CNTs
can be packed into SPE cartridges or used for dispersive solid
phase extraction.125–127 Common target analytes are small,
hydrophobic molecules extracted from water samples. Very few
applications to biouids have been reported so far. A method
for quantitation of diuretics from urine128 has been published
as well as plasma peptide analysis.129 The specicity of the
extraction can be enhanced by derivatizing the surface of CNTs
with functional groups. A method was recently shown for the
determination of anti-inammatory drugs from urine using
carboxylated CNTs for sample clean-up.130 To further improve
both specicity and handling of the sample clean-up, magnetic
CNTs coated with molecular imprinted polymers have been
synthetized and used for extraction of BSA from serum
samples.131
Restricted access materials (RAM)
Restricted access materials allow extractive clean-up of biouids
by utilizing physical and chemical diﬀusion barriers. RAM
consist of a porous material with a restrictive and hydrophilic
outer surface that prevents retention of large interfering mole-
cules such as proteins and phospholipids, combined with
smaller inner pores with hydrophobic surfaces that only mole-
cules with low molecular weight can reach.132 This technique is
commonly used for online sample clean-up, with the advantage
that samples dissolved in almost any solvent can be loaded,
even MS incompatible solvents, before elution with the mobile
phase used for chromatographic separation. There are two types
of RAM phases:133 internal surface phase (ISP) materials use size
exclusion to prevent the matrix components from reaching the
inner layer; semi-permeable surface (SPS) materials chemically
exclude matrix components by polymeric- or protein coating of
the outer layer. In both cases, the inner layer can be function-
alized to enhance the specicity of the method.134 Molecular
imprinted polymers are a special form of restricted access
materials; they are discussed below.
Application of sample clean-up using RAM includes quanti-
cation of antimicrobial agents, immunosuppressants etc. from
human biological samples prior to LC-MS/MS analysis.135,136
RAM have also been used in combination with magnetic
Fig. 5 Assembly of polymers onto the surface of magnetic nanoparticle cores (reprinted with permission from ref. 168).
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particles to quantify therapeutic drugs and steroids from bio-
uids.87,137–140 An application was published that reported the
synthesis of chiral RAMmaterials for extraction of enantiomeric
drugs from plasma samples.141
Immunosorbents
Immunosorbents use the principle of antigen–antibody aﬃnity
for highly specic retention of target substances. The desired
antibody is bound to a solid support or gel, which can be used
as SPE or micro-SPE sorbent, MEPS or in columns.123 The target
analytes can be specically extracted from complex matrices,
which allows thorough sample clean-up prior to instrumental
analysis. A study has shown that the capacity of monoclonal
antibodies was signicantly higher than that of polyclonal
antibodies.142 This technique has been used as in-tube SPME to
quantify interferon a from plasma samples143 as well as SPE
extraction of ProGRP144 and ochratoxin145 from serum. Sample
preparation techniques with high specicity towards the target
analyte are required if the target analyte is present at very low
concentration levels or in cases where structurally similar
interferents (e.g. isobars) inuence the analysis.146 The immu-
nosorbent extraction usually involves high costs, however, and
also requires host animals to grow the required antibodies.
Sometimes, the antibodies can be replaced by synthetic alter-
natives of comparable specicity, such as molecular imprinted
polymers or aptamers (see below).
Molecular imprinted polymers (MIPs)
MIPs use the principle of aﬃnity chromatography to maximize
the specicity for the analyte(s) of interest. The target analyte or
a structurally-related compound is used as a template for the
synthesis of the MIP by copolymerization of a complex formed
by the template and a functional monomer. The template
molecule is then removed, leaving a rigid three-dimensional
cavity that is complementary to the target analyte.147
The synthesis of these adsorbents is oen inexpensive and
has shown to be fast and reproducible; the materials also have
high capacity and can be regenerated and used several times.148
The MIP principle enables highly specic extraction of the
target and structurally similar compounds (e.g. a drug and its
metabolites) from complex matrices, and pre-concentration of
the sample. The specicity of this technique has been shown in
several applications. For example, a MIP sorbent developed for
tylosin was able to diﬀerentiate between tylosin and the closely
related narbomycin as well as the remotely similar tylactone.
(Fig. 6). Both the target analyte and structurally similar
compound were quantitatively extracted, whereas the inter-
fering substance did not show any aﬃnity for the sorbent.149
MIP can be used in various forms, for online or oﬀ-line
processes such as molecular imprinted solid phase extraction
(MISPE),150 magnetic MIP,151,152 solid-phase micro-extraction
(SPME), needle/micropipette tip, dynamic liquid–liquid–solid
micro-extraction (DLLSME) or molecular imprinted stir-bar
sorptive extraction (MI-SBSE).153,154 This concept has been
applied to samples with complex matrices, for example, for
benzodiazepines in plasma,155 nucleoside reverse transcriptase
inhibitors in serum,156 cocaine157 or ketamine158 from hair
extract, testosterone159 and tobacco-specic cancer
biomarkers160 from urine. MIP-coated bers for solid phase
microextraction (SPME) have also been used for extraction of
linezolid from human biouids.161 This technique has shown to
provide much cleaner extracts than other sample preparation
methods such as LLE.155 However, this technology still needs
some improvement and has several drawbacks, including
possible template bleeding, sometimes tedious synthesis
procedures, and problematic application to aqueous
samples.147,150
Aptamers
Another possibility to increase specicity for the target analyte
is the use of aptamers immobilized on a solid sorbent for
sample preparation. Aptamers are synthetic single-stranded
oligonucleotides capable of binding specic analytes with a
high aﬃnity through hydrogen bonding, van der Waals forces
and dipole interactions.123,162 They are specically prepared for
each target molecule; that is, several nucleic acids have to be
tested in vitro for each target. Selected nucleic acids with high
aﬃnity for the analytes are isolated and amplied using a
process called systematic evolution of ligands by exponential
enrichment (SELEX).163 The major advantage compared to
antibodies is that aptamers can be synthetized directly, without
the need for laboratory animals. They can be regenerated within
minutes and reused several times. The technique has been used
for the selective extraction of cocaine from plasma164,165 and for
extraction of tetracyclines from biological uids in combination
with ion mobility spectrometry.166 The high aﬃnity of a target
substance to an extraction sorbent is clearly shown in these
applications as well as the importance of the sequence of the
oligonucleotides. The sequence is specic for a particular
compound and will become inactive if the oligonucleotides are
graed in a randomized order.163 Recoveries of up to 90%
conrm the high specicity of this technique, even in complex
Fig. 6 Structures of tylosin and two structurally-related compounds,
narbomycin and tylactone.
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samples such as plasma.163 Aptamers have also been immobi-
lized on polymeric nano-bers and extraction of thrombin from
serum was shown.167
Conclusion
Common problems encountered during development of an
LC-MS/MS assay for the quantication of small molecules from
biological samples include loss of sensitivity and specicity due
to matrix eﬀects. Sample preparation is therefore an indis-
pensable part of the analytical workow. The possible inuence
of matrix eﬀects on LC-MS/MS assays has been extensively
studied and several methods have been published to identify
and avoid these eﬀects. Considerable progress has been made
in the improvement of sample preparation routines in the last
few years. New trends are directed towards either increasing the
specicity of the extraction for the target analyte or removing as
much of the matrix components as possible. Miniaturization
and automation of these techniques are on-going eﬀorts,
leading to cheaper, more robust and fully automated LC-MS/MS
assays that will signicantly impact pharmaceutical analyses of
biouids in the future.
List of abbreviations
APCI Atmospheric pressure chemical ionization
BSA Bovine serum albumin
CNT Carbon nanotubes
CSF Cerebrospinal uid
DART Direct analysis in real time
DESI Desorption electrospray ionization
DLLSME Dynamic liquid–liquid–solid microextraction
DTT Dithiothreitol
ESI Electrospray ionization
GC–MS Gas chromatography-mass spectrometry
GPCho Glycerophosphocholines
HILIC Hydrophobic interaction liquid chromatography
IS-MRM In-source multiple reaction monitoring
ISP Internal surface phase
LC-MS Liquid chromatography-mass spectrometry
LC-MS/
MS
Liquid chromatography-tandem mass spectrometry
LLE Liquid–liquid extraction
MALDI Matrix-assisted laser desorption/ionization
MEPS Microextraction by packed sorbent
MIP Molecular imprinted polymers
MI-SBSE Molecular imprinted stir-bar sorptive extraction
MISPE Molecular imprinted solid phase extraction
MNP Magnetic nanoparticles
MRM Multiple reaction monitoring
MTBE Methyl-tert-butylether
MWCNT Multi-walled carbon nanotubes
PPL Phospholipids
PPT Protein precipitation
PQ Piperaquine
PS–DVB Polystyrene–divinylbenzene
RAM Restricted access materials
SALLE Salt-assisted liquid–liquid extraction
SELEX Systematic evolution of ligands by exponential
enrichment
SLE Supported liquid extraction
SPE Solid-phase extraction
SPME Solid-phase microextraction
SPS Semi-permeable surface
SWCNT Single-wall carbon nanotubes
TCEP Tris(2-carboxyethyl)phosphine
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Simultaneous quantiﬁcation of acetaminophen
and structurally related compounds in human
serum and plasma
Caroline Bylda,a,b Roland Thiele,a Uwe Kobolda and Dietrich A. Volmerb*
The method described in this study allows the simultaneous quantiﬁcation of acetaminophen (APAP) and nine structurally related
compounds, namely acetaminophenmetabolites and structurally similar analogs (acetaminophen-glucuronide [APG], -sulfate [APS],
mercapturate [APM], -cysteine [APC], p-phenetidine, phenacetin), antidote (N-acetylcysteine, NAC), and two tricyclic antidepressants
(imipramine and amitryptiline). Due to the relatively high serum concentration levels in the μg/ml range, matrix effects were simply
minimized by dilution. The samples were diluted with water and disulﬁde bonds between serum proteins and analytes reduced
using tris(2-carboxyethyl)phosphine. Chromatographic separation of the analytes was achieved by gradient elution using a
pentaﬂuorphenyl (PFP) column with subsequent detection by electrospray ionization (ESI) triple quadrupole mass spectrometry
in positive and negative ionization multiple reaction monitoring (MRM) modes. Quantiﬁcation was performed by means of deuter-
ated analogues of the analytes as internal standards. Total run time of the assay was 19min. The method was fully validated and
allowed quantiﬁcation of the analytes with lower limits of quantiﬁcation between 50 and 0.5ng/ml. The calibration curves were
linear over the range 0.1–100μg/ml for APAP, APG, NAC, p-phenetidine and phenacetin, 0.03-50μg/ml for APS, and 0.01-10μg/
ml for APM, APC, imipramine and amitriptyline with correlation coefﬁcients r2> 0.99. The intra-assay precision was ≤5% for all
analytes except NAC (CV< 10%). The inter-day precision was ≤10% for all analytes except NAC (inter-assay precision <11%). This
method was used to analyze 77 patient and spiked samples and results were consistent with expected values from a round robin
test. Copyright © 2013 John Wiley & Sons, Ltd.
Keywords: acetaminophen; LC-MS/MS; immunoassay; metabolites; serum; plasma
Introduction
Acetaminophen (APAP, N-acetyl-p-aminophenol), also known as
paracetamol, is a widely used over-the-counter drug with anal-
gesic and anti-pyruvic properties. Severe toxic effects in case
of an overdose or long-term abuse have been reported.[1] In
Europe and the United States, the daily limit is 4 g[2]; in Japan
it is set at 1 g.[3] The lethal dose strongly varies between individ-
uals, depending on health condition, drinking habits, and
age.[4,5] The threshold for liver damage is known to be approx-
imately 250mg/kg.[6] APAP poisoning is accompanied by
unspeciﬁc symptoms such as nausea, vomiting, pallor, and
lethargy in the ﬁrst 24 h. It may take up to 48 h before signs of
hepatic failure become apparent.[7]
APAP undergoes several metabolic pathways and exhibits a
number of metabolites. The abbreviated metabolism of acet-
aminophen in the human body is summarized in Figure 1.[8–10]
Brieﬂy, APAP is primarily metabolized to stable glucuronic acid
(APG) and sulfate (APS) metabolites. A small proportion of APAP
is transformed by cytochromes P450 2E1 to the highly reactive
metabolite N-acetyl-p-benzoquinoneimine (NAPQI),[11] which is
normally detoxiﬁed by conjugation with glutathione. This com-
plex further reacts to acetaminophen-cysteine (APC) and then
to acetaminophen-mercapturate (APM).[12] Excessive dosage of
APAP causes overproduction of this metabolite and depletion
of free glutathione. In this case, NAPQI binds to liver cell
proteins, causing hepatic necrosis. In aqueous medium, NAPQI
undergoes redox reactions andhydrolysis anddecomposes to further
products, whichmakes quantiﬁcation in serum very difﬁcult.[13,14]
The damaging action of NAPQI can be stopped by adminis-
tration of N-acetylcysteine (NAC). The antidote inhibits binding
of NAPQI to liver proteins by creating a new source of free
glutathione, and also has the ability to directly bind to NAPQI
and thus detoxify it.[15,16] However, the second mode of action
was shown to have little relevance for the detoxiﬁcation process
of APAP.[17]
Phenacetin was commonly used as an analgesic at the end of
the twentieth century. Because of dangerous side-effects, it has
been taken off the market in a number of countries. The main
metabolite of phenacetin is APAP, but p-phenetidine is also
formed by deacylation.[18]
Imipramine and amitriptyline are tricyclic antidepressants,
which in certain instances are co-administered with APAP. Prelim-
inary tests at Roche Diagnostics during the development of an
immunologic APAP assay showed that these substances have
the potential to cross-react with immunologic assays.
* Correspondence to: Dietrich A. Volmer, Saarland University, Institute of
Bioanalytical Chemistry, D-66123 Saarbrücken, Germany. E-mail: Dietrich.
Volmer@mx.uni-saarland.de
a Roche Diagnostics GmbH, Penzberg, Germany
b Institute of Bioanalytical Chemistry, Saarland University, Saarbrücken, Germany
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Usually APAP is quantiﬁed by immunoassay techniques, either as
part of a general screen or as speciﬁc target.[19–25] Various other an-
alytical methods have also been applied to detect APAP and its me-
tabolites, such as high performance liquid chromatography (HPLC)
in combination with accelerator mass spectrometry (AMS),[26] di-
ode-array detection (DAD),[8] chemical reaction interface for mass
spectrometry (CRIMS),[27] UV,[9] as well as capillary electrophoresis
(CE) with UV detection.[28] In particular, hyphenated HPLC-mass
spectrometry (LC-MS) has shown great potential, because of its
speciﬁcity and its ability to identify structurally-related substances
that could bias the result of immunoassay analysis. Several LC-MS
methods have been reported for quantiﬁcation of APAP[29] or APAP
in combination with other analytes, for example other therapeutic
drugs,[30–33] or several metabolites in various matrices.[25,34–39] An
assay for APAP and all major metabolites was reported for rat
plasma.[25] It is essential that methods developed for clinical diag-
nostics are carefully validated for potential matrix interferences.
The sample material usually exhibits a strong inﬂuence on the
method performance; therefore, methods developed for sample
matrices other than human serum cannot be readily transferred
without proper evaluation and modiﬁcations. To our knowledge,
there is no literature LC-MS method for quantifying APAP simulta-
neously with its major metabolites in human serum and plasma.
Mass spectrometric quantiﬁcation of NAC has been de-
scribed.[33,40] Phenacetin and p-phenetidine have been included
in LC-MS assays for APAP and of its metabolites.[18,41] One study
has also reported the simultaneous LC-MS analysis of APAP,
imipramine and amitriptyline (amongst others),[42] but no
method is available to simultaneously quantify the combina-
tion of substances presented in this work in human serum
and plasma.
The scope of this work was the development and optimization
of a simple, speciﬁc and sensitive LC-MS/MS method for quantiﬁ-
cation of APAP, its main metabolites and several structurally
Figure 1. Abbreviated metabolic pathway of acetaminophen and chemical structures of the investigated analytes (a); chemical structures of the
isotopically labelled standards (b).
C. Bylda et al.
Drug Testing
and Analysis
wileyonlinelibrary.com/journal/dta Copyright © 2013 John Wiley & Sons, Ltd. Drug Test. Analysis (2013)
Publication 2
34
related compounds in serum as a reference method for an
APAP-targeted immunoassay.
Experimental
Reagents and chemicals
The reference material for APAP was purchased from LGC
Standards (Wesel, Germany). Imipramine was from Cerilliant
(Wesel, Germany) at 1mg/ml in methanol. Amitriptyline was
from Sigma-Aldrich (Steinheim, Germany) and all other analytes
(4-acetamidophenyl β-D-glucuronide sodium salt, 4-acetamino-
phen sulfate potassium salt , 3-(N-acetyl-L-cystein-S-yl) acetami
nophen sodium salt , 3-cysteinylacetaminophen triﬂuoroacetic
acid salt , N-acetyl-L-cysteine , p-phenetidine, phenacetin) were
purchased from Toronto Research Chemicals (Toronto, ON,
Canada). Deuterated analogues of the analytes were used as
internal standards. Imipramine-d3 was ordered from Cerilliant
and amitriptyline:HCl (N,N-dimethyl-d6) from Cambridge Iso-
tope Laboratories (Saarbrücken, Germany) at 100 μg/ml in
methanol. The deuterated substances APAP-d3, APAP-d4, 4-ace
tamidophenyl β-D-glucuronide-d3 sodium salt (APG-d3), 4-acet-
aminophen-d3 sulfate (APS-d3), 3-(N-acetyl-L-cystein-S-yl) acetami
nophen sodium salt-d5 (APM-d5), 3-cysteinylacetaminophen-d5
triﬂuoroacetic acid salt (APC-d3), p-phenetidine-d5 hydrochloride,
phenacetin-d5 were from Toronto Research Chemicals. LC-MS
grade solvents were from Biosolve (Valkenvaard, the Netherlands).
Formic acid (FA) (98-100%) was purchased from Merck (Darmstadt,
Germany) and tris(2-carboxyethyl)phosphine (TCEP) from Sigma-
Aldrich. Human serum for therapeutic drug monitoring
provided by Roche Diagnostics GmbH (Mannheim, Germany)
was used as negative calibrator matrix. Water was generated
using a Waters Millipore Milli-Q-Plus puriﬁcation system
(Eschborn, Germany)
Sample preparation
A serum volume of 25μl was used for each analysis. Each sample
was mixed with 25μl internal standard solution and 400μl MilliQ
water in an Eppendorf vial and equilibrated at room temperature
while shaking on a thermomixer for 15min. Fifty microliters of a
350mmol/L TCEP solution were then added to the vial and the
sample mixed again for 30min at 37 °C. After this reduction step,
the solution was transferred to an ultracentrifugation tube using
a regenerated cellulose 30 kDa cutoff membrane. The acidic
ﬁltrate (pH between 3 and 4) was then injected into the LC-MS/
MS system.
Quantiﬁcation
Calibration samples were prepared by spiking analyte-free human
serum with a stock solution containing all analytes. Depending on
the expected concentration levels of the substances in human
serum, different amounts for each substance were spiked into
the calibrator samples. APAP, APG, NAC, p-phenetidine and phen-
acetin were spiked in concentrations between 0.1 and 100μg/ml,
APS between 0.03 and 50μg/ml and APM, APC, imipramine and
amitriptyline between 0.01 and 10μg/ml. The concentrations of
all calibrators for each analyte are shown in Table 1. Deuterated
internal standards were added to each sample at different concen-
tration levels. APAP-d3 and APG-d3 at 50μg/ml, APS-d3 at 25μg/ml,
APAP-d4 at 10μg/ml, APM-d5, APC-d5, p-phenetidine-d5 and phen-
acetin-d5 at 5μg/ml and imipramine-d3 and amitriptyline-d6 at
2.5μg/ml.
The compounds were quantiﬁed using the multiple reaction
monitoring (MRM) mode of the mass spectrometer. Calibration
curves were constructed using analyte/internal standard peak
area ratios for all analytes. Unknown samples were quantiﬁed
by comparing the ratio of the integrated area of the analyte
and the corresponding internal standard to the corrected
calibration curve.
Chromatography and mass spectrometry
The chromatographic system consisted of Dionex (Germering,
Germany) U3000 binary pump, column oven and autosampler.
The analytes were separated on a Phenomenex (Aschaffenburg,
Germany) Kinetex PFP column (2.6μm, 150 x 3.0mm, 100Å).
The mobile phase was acetonitrile-water (5:95 v/v) + 0.1% formic
acid (eluent A), acetonitrile:water (50:50 v/v) + 0.1% formic acid
(eluent B) and acetonitrile + 0.1% formic acid (eluent C). Gradient
elution at a ﬂow rate of 300μl/min was performed (Table 2). The
total runtime of analysis was 19min. The column temperature
was maintained at 40 °C during separation.
The mass spectrometer was a Thermo Scientiﬁc (Bremen,
Germany) TSQ Vantage triple quadrupole equipped with a
heated electrospray ionization source (HESI). The sprayer
voltage was set to +4500 V in positive and -3250 V in negative
ionization mode, capillary temperature was kept constant at
250 °C, nitrogen as sheath gas was set to 60 psi, the HF ampli-
tude of the S-Lens was 87 V, and the argon pressure in the
collision cell 1 mTorr. The multiple reaction monitoring (MRM)
transitions and optimized collision energies (CE) for each transi-
tion are summarized in Table 3.
Table 1. Concentrations of all investigated analytes in the calibrators [μg/ml]
Cal # APAP APG APS APC APM NAC Phene-tidin Phena-cetin Imipra-min Amitrip-tylin
0 200.0 200.0 100.0 20.0 20.0 200.0 200.0 200.0 20.0 20.0
1 100.0 100.0 50.0 10.0 10.0 100.0 100,0 100.0 10.0 10.0
2 50.0 50.0 25.0 5.00 5.00 50.0 50.0 50.0 5.00 5.00
3 30.0 30.0 15.0 3.00 3.00 30.0 30.0 30.0 3.00 3.00
4 10.0 10.0 5.00 1.00 1.00 10.0 10.0 10.0 1.00 1.00
5 5.00 5.00 2.50 0.50 0.50 5.00 5.00 5.00 0.50 0.50
6 1.00 1.00 0.50 0.10 0.10 1.00 1.00 1.00 0.10 0.10
7 0.75 0.75 0.38 0.08 0.07 0.75 0.75 0.75 0.07 0.07
8 0.05 0.05 0.03 0.01 0.01 0.05 0.05 0.05 0.01 0.01
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The total acquisition time was divided into ﬁve segments, to
increase the number of data points per peak. The ﬁrst segment
was further divided in two scan events, where the polarity was
constantly switched between positive and the negative ioniza-
tion mode, to record transitions of APC, APG and their deuterated
standards (positive mode) as well as transitions of NAC (negative
mode). During the following 0.9min, APAP, APS, p-phenetidine
and their internal standards were recorded as well as APAP-
d4 used as internal standard for NAC. In the third segment
(5.8–7.8min), p-phenetidine and APM plus deuterated stan-
dards were monitored. The fourth segment (7.8–11.6min)
was for phenacetin and phenacetin-d5. During the remainder
of the chromatographic run, imipramine, amitriptyline and
their internal standards were monitored.r
Method validation
System suitability test
At the beginning of each sequence, the following system
suitability test was carried out: an aqueous solution of all analytes
at the concentration level of Cal 8 (Table 1) was injected into the
system. Signal-to-noise ratios for all analytes were required to be
10:1. Additionally, it was checked whether all peaks appeared
inside their intended time segments.
Accuracy, precision
The accuracy was determined for all analytes with three replicates
at three concentration levels, by comparing calculated concentra-
tions with the theoretical values. For this procedure, different
concentrations of analytes were spiked into analyte-free matrix.
These concentrations are given in Table 4. For the main analyte
APAP, the purity of the reference material was investigated by sev-
eral analytical methods. The APAP content of the materials was
determined by quantitative nuclear magnetic resonance (qNMR),
the percentage of inorganic impurities was investigated using in-
ductively coupled plasma mass spectrometry (ICP-MS) and the
slopes of the calibration curves were compared by HPLC-MS/MS.
The quality of the used reference material was compared to other
materials, namely Sigma Aldrich BioXtra and Sigma Aldrich ‘meets
USP qualiﬁcations’. Recovery was calculated in terms of bias as
percent deviation of the measured mean from the corresponding
theoretical concentration. Precision was evaluated by performing
six determinations at three concentration levels (low, mid, and
high). Each sample was analyzed in duplicate. The intra-assay pre-
cision was calculated for the mean of all six preparations. For the
inter-assay precision, the same experiment was repeated by a dif-
ferent operator on a different day. The coefﬁcient of variation
(CV) was determined using all 12 measurements for each concen-
tration level.
Speciﬁcity, ion suppression[43,44]
Possible matrix-dependent ion suppression effects were assessed.
The possible transfer of this method to different matrices such as
plasma collected in Lithium-heparin or EDTA-tubes was also
investigated. The speciﬁcity of the method was also veriﬁed by
analyzing analyte-free serum and plasma samples. Ion suppression
from glycerophosphocholines (GPCho) was measured in selected
ion monitoring (SIM) mode over the entire run by monitoring the
ion at m/z 184 and 104 formed by in-source collision-induced
dissociation (CID) using a high declustering voltage of themass spec-
trometer (40V). All GPCho compounds yield the common product
Table 2. Eluent gradient composition of the gradient
Time [min] %B %C
0 0 0
6 50 0
13 0 100
16 0 100
16.1 0 0
19 0 0
Table 3. MRM transitions and applied collision energies (CE [V], in parentheses) for all investigated substances and their corresponding internal standards
Compound MRM transition Internal standard MRM transitions
APAP m/z 152.1 ➔ 65.0 ( 25), 110.0 (15) APAP-d3 m/z 155.1 ➔ 65.0, 111.1 (25)
APG m/z 328.1 ➔ 151.9 (18) APG-d3 m/z 331.0 ➔ 154.8 (18)
APS m/z 231.9 ➔ 109.9, 151.9 (18) APS-d3 m/z 234.9 ➔ 110.9, 154.9 (18)
APM m/z 313.1 ➔ 165.8, 207.9 (20) APM-d5 m/z 318.1 ➔ 167.8, 212.0 (20)
APC m/z 271.0 ➔ 140.0, 182.0 (18) APC-d5 m/z 276.1 ➔ 142.9, 186.7 (18)
NAC m/z 161.6 ➔ 28.1, 81.3, 161.6 (10) APAP-d4 m/z 156.1 ➔ 69.1, 114.1 (23)
p-Phenetidine m/z 138.1 ➔ 93.0, 110.0 (20) p-Phenetidine-d5 m/z 143.1 ➔ 93.0, 111.0 (18)
Phenacetin m/z 180.0 ➔ 110.0, 138.1 (22) Phenacetin-d5 m/z 185.1 ➔ 111.0, 143.1 (18)
Imipramine m/z 281.2 ➔ 58.0, 86.0 (25) Imipramine-d3 m/z 284.2 ➔ 61.1, 89.1 (25)
Amitriptyline m/z 278.2 ➔ 90.9, 233.1 (20) Amitriptyline-d6 m/z 284.3 ➔ 91.0, 233.1 (25)
Table 4. Concentrations of all analytes in samples used for the
validation of the method
Substances High level
[μg/ml]
Middle level
[μg/ml]
Low level
[μg/ml]
APAP 50 10 1
APG 50 10 1
APS 25 5 0.5
APM 5 1 0.1
APC 5 1 0.1
NAC 50 10 1
p-Phenetidine 50 10 1
Phenacetin 50 10 1
Imipramine 5 1 0.1
Amitryptiline 5 1 0.1
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ion (trimethylammonium-ethylphosphate, m/z 184) that sometimes
further dissociates to trimethylammoniumethylate (m/z 104).[44]
Linearity, sensitivity
The linearity of the method was assessed by extending the 8-point
calibration range from 80% of the lowest concentration to 120% of
the highest calibrator. The lower limit of quantiﬁcation (LLOQ) in
serum was determined using the isotopically labelled substances,
because of small endogenous amounts of analyte already contained
in the samplematrix. The LLOQwas deﬁned as the lowest concentra-
tion measured with a CV< 20% over six measurements.
Stability
Stability of the samples was determined by storing serum
calibrators containing all 10 analytes at 4 °C and -20 °C for
seven days and comparing the recovery before and after stor-
age. Additionally, serum samples containing only APAP were
stressed at temperatures ranging from -20 °C to 35 °C for up
to 12 weeks. The APAP amount was determined before the
beginning of the experiment. Sample aliquots were then ana-
lyzed after one day and after one, three, six and twelve weeks,
and recoveries calculated compared to the original value.
Results and discussion
The aim of this study was the development of LC-MS/MS refer-
ence method for quantiﬁcation of the very common analgesic
drug, APAP, its antidote and several structurally related com-
pounds (including metabolites) known to cross-react with
APAP-speciﬁc immunoassays. The main requirement for this
method was the ability to quantify the analytes in serum
samples as well as the possibility to transfer the technique to
plasma samples (heparin and EDTA tubes). The calibration
range of APAP was 0.1–100 μg/ml; calibration ranges for the
other analytes were adapted to the expected concentration
levels in human serum based on the metabolism of the parent
drug, and on therapeutic ranges for the other quantiﬁed sub-
stances. The very broad polarity range of the target substances
put limitations on the sample preparation protocol. After a
reduction step to cleave disulﬁde bonds between target mole-
cules and matrix proteins, the samples were diluted and ﬁltered
before injection into the LC-MS/MS system.
Optimization of sample preparation
The samples were ﬁrst incubated by rolling the tubes for 15min
with the internal standard solution. This step allowed equilibra-
tion of the analytes with the deuterated standards and
improved the reproducibility of the method. After initial experi-
ments, it became clear that N-acetylcysteine was not detectable
in serum without pretreatment. Therefore, a reduction agent
was used to cleave the disulﬁde bonds between N-acetylcysteine
and proteins from the sample matrix. Two reducing agents were
tested, DTT and TCEP. The test results showed that DTT needed
longer incubation times than TCEP and had an unpleasant odor.
Therefore, TCEP was chosen as reducing agent. Because of the
wide spectrum of polarities of the target analytes, a simple
sample preparation approach (dilution/ﬁltration) was initially
investigated before more complex and time-consuming
methods such as solid-phase extraction (SPE) or liquid/liquid
extractions (LLE). Fortunately, the detection sensitivity of the
LC-MS/MS far exceeded the required sensitivity from the
analytes in the samples. Therefore, matrix effects were simply
‘diluted out’.
Optimization of LC-MS conditions
Several reversed-phase materials (Waters XTerra C18, Phenomenex
Kinetex C18, Agilent Zorbax C8 and SB-CN, Thermo Fisher Scientiﬁc
Hypercarb, Phenomenex Kinetex PFP) were tested for the chromato-
graphic separation of the analytes. Optimum results were achieved
with the pentaﬂuorphenyl-phase (PFP) column, which allowed
resolving the very polar APAP metabolites and separation of this
group of compounds from other, less polar analytes (Figure 2).
Ionization for LC-MS was performed via electrospray ioniza-
tion (ESI). Optimization of ionization and fragmentation condi-
tions was performed using standard solutions of each analyte.
All analytes except for NAC exhibited high sensitivity in positive
ionization mode. NAC showed better results in negative ioniza-
tion mode; polarity of ionization was therefore switched during
each run. A compromise for interface conditions had to be used
to detect all analytes with sufﬁciently high sensitivity. Since
APAP was the primary target, the optimum settings for ioniza-
tion of APAP were applied to all other target molecules (i.e. set-
tings for capillary temperature, sheath gas pressure, sprayer
voltage and S-Lens potential). Fragmentation conditions were
optimized as well; in these experiments, the collision gas
pressure was kept constant for all analytes and the collision
energy was optimized for each MRM transition. For MRM, the
two most intense and selective product ions were chosen for
each target substance. Unspeciﬁc transitions such as H2O or
CO2 losses were avoided. The collision energy was set to the
value for which the sum of the intensities of both product ions
was the highest.
Ion suppression
Ion suppression effects from the matrix were assessed by
continuous post-column infusion of the analyte after injection
of a processed blank serum sample. Any variation of signal in-
tensity near the retention times of the analytes would indicate
the presence of substances from the matrix interfering with
the analysis.[43] For this experiment, 10 serum blank samples
were processed in identical manner to the regular samples.
The ﬁltrates were pooled and equally distributed over 10 vials.
The experiment was carried a single time for each analyte. No
sudden increases or decreases of signal intensities were noticed
close to the retention time of the target analytes. The observed
chromatogram for APAP is shown in Figure 3. The matrix does
not seem to contain any substance that interferes with quantiﬁ-
cation of the analytes.
An additional experiment was carried out to assess the
speciﬁc inﬂuence of glycerophosphocholines (GPCho), which
are known to cause matrix ionization effects in LC-MS/MS
methods[44] (see Experimental for experimental details).
Analyte-free serum and plasma samples were processed and
injected into the LC-MS-system. In all tested matrices, no signal
was recorded for the fragments of GPCho compounds at the
retention time of the analytes. This experiment conﬁrmed that
the sample matrix does not interfere with the quantiﬁcation of
the analytes.
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Traceability of the reference material
The purity of our reference material was examined to ensure
the traceability of the method. Several techniques of analysis
were employed to characterize the reference substance for
APAP (USP reference standard, [A]) and two similar materials
(Sigma ‘meets USP speciﬁcations’ [B] and Sigma ‘BioXtra quality’
[C]). Analysis by qNMR showed that absolute APAP content of
these materials was between 98.8% and 98.9%. The percentage
of inorganic impurities was determined by ICP-MS. Substance A
exhibited the highest purity containing only 11mg/kg silicon.
Both Sigma materials also showed traces of inorganic impurities:
B contained 15mg/kg silicon and 18mg/kg potassium, whereas
C contained 1mg/kg silicon and 14mg/kg calcium. Analysis by
LC-MS/MS showed a variation of 3% in the slopes of calibration
curves determined from these materials, the slope of the USP
standard being slightly lower than the Sigma materials.
Transferability to plasma samples
The assay was originally developed for quantiﬁcation of acet-
aminophen and the other analytes from serum. To determine
whether this method could also be adapted to plasma samples,
two sets of calibrators were prepared, one in EDTA and a second
in a heparin plasma pool of nine donors. These samples were
processed as usual and compared to the reference calibration
Figure 2. MRM chromatographic traces of the ﬁrst (A) and second (B) group of substances eluting from the HPLC column. Sample: human serum,
analyte concentration range, 1.0–10μg/ml.
Figure 3. Post-column infusion of APAP in analysis of processed matrix blank.
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curve in human serum for therapeutic drug monitoring. The
regression equations of all three calibration curves were
compared: the variation of the slopes was 2%. The slopes of
the calibration curves in plasma were both smaller than the
calibration curve in serum. These values are well within with
the speciﬁcations of the method, thus it is readily possible to
quantify the panel of analytes in plasma with this assay.
Validation
The investigated concentration levels of the target analytes in the
samples ‘low’, ‘mid’ and ‘high’ are given in Table 4. These levels
were used to assess precision and accuracy of the method.
The accuracy of the method was determined by comparing
the average measured concentration of a spiked sample (n= 3
preparations) to the originally spiked amount. The values were
between 95% and 101% for the high level, 92% and 102% for
the mid level and 92% and 105% for the low level.
The calculated CVs for intra- and inter-assay precision are
summarized in Table 5. All intra- and inter-assay coefﬁcients
were lower than 5% and 7%, respectively, showing overall good
precision of the method. NAC was considered separately as
precision values for this substance were higher than for other
analytes because no isotopically labelled standard was available
for this analyte and the chosen internal standard did not have
the same binding afﬁnity to proteins than NAC. The reduc-
tion step with TCEP, where cleavage of disulﬁde bonds
between NAC and serum proteins occurs, was therefore not
compensated by an internal standard, ultimately resulting in
higher imprecision.
The linearity of the method was investigated for each analyte
by adding two points to the calibration curve and measuring
them three-fold. The coefﬁcients of regression were determined
for these new calibration curves; they were always> 0.992, thus
demonstrating good linearity for all analytes in the desired
calibration ranges.
The detection sensitivity was assessed by spiking several
concentrations of target analytes below the smallest calibrator
level into therapeutic drug-free-serum. These samples were
measured six times; the lower limits of quantiﬁcation (LLOQ)
with corresponding CV values are summarized in Table 6 for
each target molecule. This experiment was not carried out
for NAC, because the LLOQ for this analyte corresponded to
the lowest concentration of the calibration range.
The investigated calibration ranges were different for all
target analytes; they were chosen according to expected
concentrations found in the human body. The main focus of this
method was not to achieve high detection sensitivity for all
substances, but rather to be able to detect signs of possible
poisoning with APAP or to show the presence of other thera-
peutic drugs capable of falsifying the results of the immunoas-
say screening. Therefore, it was only required to achieve low
LLOQ values for APC and APM as they represent only 5-10% of
the metabolic pathway of APAP, and for imipramine and ami-
triptyline, because these drugs are not prescribed in high doses.
For the other substances, the main focus was to achieve a
robust method with linearity over a broad concentration range.
The stability of the calibrators was investigated by determin-
ing the recovery of the target substances after 2 and 7 days
storage at different temperatures. The calibrators were
prepared and analyzed on day 1 and aliquots were stored at
4 °C and -20 °C. Aliquots were taken out and measured again
after 2 and 7 days storage time. The regression coefﬁcients
and slopes of the calibration curves were compared to analysis
of calibrators on day 1. All coefﬁcients of regression were
0.991 and the variation of the slopes was ≤ 6%, regardless of
the storage temperature. The mixed calibrators in serum can
be stored at 4 °C or -20 °C for at least one week. Additionally,
the shelf-life of the samples was simulated with an accelerated
testing model based on the Arrhenius equation. Using this
model, the long-term stability can be estimated by observing
Table 5. Precision of the assay
Substances Precision high level (%) Precision middle level (%) Precision low level (%)
Intra-assay (n = 6) Inter-assay (n = 12) Intra-assay (n = 6) Inter-assay (n = 12) Intra-assay (n = 6) Inter-assay (n = 12)
APAP 2 4 3 4 5 5
APG 2 3 3 4 5 5
APS 1 3 2 3 4 4
APM 2 3 2 3 4 3
APC 2 3 3 4 5 4
NAC 3 4 3 5 10 11
p-Phenetidine 2 7 4 6 5 4
Phenacetin 2 2 2 3 5 7
Imipramine 1 3 2 3 2 3
Amitryptiline 1 3 3 4
Table 6. Lower limits of quantiﬁcation (LLOQ) and coefﬁcients of
variation (CV)
Substance LLOQ [ng/ml] CV [%]
APAP-d3 20 ng/ml 17
APG-d3 40 ng/ml 15
APS-d3 24 ng/ml 13
APM-d5 4 ng/ml 17
APC-d5 0.5 ng/ml 11
NAC 50 ng/ml n.a.
p-Phenetidine-d5 40 ng/ml 15
Phenacetin-d5 10 ng/ml 14
Imipramine-d3 1 ng/ml 12
Amitryptiline-d6 1 ng/ml 11
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the degradation rates at high temperatures.[45] For this exper-
iment, blank serum samples were spiked with 5 APAP
concentrations and were stressed at -20 °C, 2–8 °C, 25 °C and
35 °C for a total time of 12 weeks, simulating a storage of up
to 5 years at -20 °C. Aliquots were regularly taken and ana-
lyzed, and the obtained values compared to the measured
concentrations on the day of the spiking. The recoveries for
the aliquots measured after 12 weeks are shown in Table 7.
These results demonstrate that serum samples containing
APAP are stable up to ﬁve years when stored at -20 °C.
Application to analysis of patient and spiked samples
After validation, the method was used to analyze a total of 77
samples. Nine of these samples were anonymized patient
samples from an unrelated study, while other samples were
obtained by spiking analyte-free matrix. For these samples,
serum of healthy volunteers was collected and treated in
agreement with the local ethics guidelines (Ethik Kommission
der Bayerischen Landesärztekammer – # 11101, January 2012).
The APAP content of these samples was previously measured
by immunoassay in the context of a round robin trial. The values
obtained with our method were compared to the overall result
of the round robin trial as shown in Figure 4. Regression analysis
with Passing/Bablok showed the following coefﬁcients: slope,
1.0217 and intercept, 0.1350. This data shows good correlation
of the result for APAP with both methods. The content of
metabolites and structure-related compounds was also
determined in the patient samples with LC-MS/MS. No APAP
structure-related substance capable of biasing the result of
the immunoassay was detected. However, high concentrations
of metabolites were found in some patient samples (Table 8).
The high NAC concentrations found in these samples indicate
that the patients had already been treated with the antidote.
These results also illustrate that APAP is quickly metabolized
and that the ability to quantify the metabolites is potentially
of much higher importance than simply measuring the parent
drug in cases of drug overdose.
Conclusions
An LC-MS/MS assay for quantifying APAP in human serum was
developed in this study. The metabolites of the parent drug, a
commonly used antidote and four other substances structurally
related to the target analyte were also quantiﬁed with the same
method. The samples were reduced using TCEP and ﬁltered by
ultracentrifugation with a cut-off membrane before chromato-
graphic separation and quantiﬁcation by LC-MS/MS using
deuterated standards. The method was fully validated and
exhibited good precision with intra- and inter-day precisions
between 1% and 7% (exception: NAC with values between 3%
and 11%). The linearity of the assay was demonstrated over
the calibration range of all analytes, with coefﬁcients of regres-
sion> 0.99. LLOQ of APAP was 20 ng/ml. For all other sub-
stances, LLOQ varied between 0.5 ng/ml and 50 ng/ml.
Table 7. Long-term stability of serum samples spiked with
acetaminophen
Sample
# Conc. at
t=0
Recoveries after simulation of
long-term storage at -20 °C (%)
[μg/ml] 5 years
(12weeks 25 °C)
5 years
(6weeks 35 °C)
A Blank
B 10.2 96 100
C 73.6 96 96
D 100.8 97 103
E 293.8 95 103
F 501.6 96 103
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Figure 4. Comparison of measured LC-MS/MS concentration values for
77 samples (spiked and patient samples) with previously measured im-
munoassay values from Round Robin test.
Table 8. Concentrations of all investigated analytes in patient serum samples
Conc. [μg/ml] #1 #2 #3 #4 #5 #6 #7 #8 #9
APAP 37 23 23 40 63 45 12 75 17
APG n.d. 76 > 100 > 100 > 100 28 47 > 100 66
APS 47 23 41 50 36 20 11 90 37
APM 0.4 0.3 0.4 0.3 0.2 0.2 0.9 0.3 1.2
APC 1.6 1.4 2.0 1.6 0.8 1.2 13 1.8 3.2
NAC >100 82 100 >100 >100 n.d. n.d. >100 >100
p-Phenetidine n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Phenacetin n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Imipramin n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Amitriptylin n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
n.d., not detected
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Although the calibrators were serum-based, this method also
allowed quantiﬁcation of the analytes in plasma samples
(collected with EDTA or lithium heparin tubes).
To our knowledge, no other method has been reported that
allows this combination of substances to be determined simul-
taneously. The method is a useful tool to help diagnose and
conﬁrm APAP overdoses. Its potential has been demonstrated
during the analysis of 77 samples. It showed good correlation
to the average results of a round robin trial based on immuno-
assay-analysis.
The main purpose of this method is the future use as refer-
ence method for an immunoassay-based APAP-test, which can
be biased by metabolites of the target analytes or other thera-
peutic drugs with similar structures and therefore generate
false-positive results.
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Magnetic beads as an extraction medium for
simultaneous quantification of acetaminophen
and structurally related compounds in
human serum
Caroline Bylda,a,b Vanya Velichkova,a Jens Bolle,a Roland Thiele,a
Uwe Kobolda and Dietrich A. Volmerb*
This paper describes a sample preparation method that complements a previously published liquid chromatography-tandem
mass spectrometry (LC-MS/MS) assay for acetaminophen and eight structurally-related compounds in human serum (C. Bylda,
R. Thiele, U. Kobold, D.A. Volmer. Drug Test. Anal. 2014, 6, 451). The analytes (acetaminophen [APAP]+metabolites
acetaminophen-glucuronide [APG], -cysteine [APC], -mercapturate [APM] and -cysteine [APC], structurally similar analogues
phenacetin and p-phenetidine, as well as tricyclic antidepressants imipramine and amitryptiline) were extracted from serum using
magnetized hyper-crosslinked polystyrene particles. The sample preparation protocol was developed by means of a design of ex-
periments (DoE) statistical approach. Using three representative compounds from the analyte panelwith different polarities (high,
medium, and low), two screening designs were used to identify factors that exhibited significant impact on recovery of the
analytes. These parameters were then optimized to permit extraction of the complete target panel exhibiting a broad range of
chemical polarities. Liquid chromatographic separations were achieved by gradient elution using a pentafluorphenyl columnwith
subsequent detection by electrospray ionization-triple quadrupole mass spectrometry in multiple reaction monitoring (MRM)
mode. The method was linear over the range 0.1–100μg/mL for APAP, APG, p-phenetidine and phenacetin, 0.03–50μg/mL for
APS, and 0.01–10μg/mL for APM, APC, imipramine and amitriptyline, with R2> 0.99. The assay exhibited good precision with
CVs ranging from 2 to 9% for all analytes; the accuracy was assessed by comparing two LC-MS/MS methods using a set of 68
patient samples. Copyright © 2014 John Wiley & Sons, Ltd.
Keywords: acetaminophen; magnetic beads; LC-MS/MS; design of experiments
Introduction
The pharmaceutical industry is continuously seeking to improve its
analytical assays, generally to perform analyses that are faster,
cheaper, and more reliable. Efforts at automating liquid
chromatography-tandem mass spectrometry (LC-MS/MS) assays
are often aimed at improving the sample preparation step. Mag-
netic particles have recently attracted considerable interest from
analytical scientists, because they offer the unique ability of rapid
and specific sample extraction and clean-up that can be readily
automated.[1,2] These particles consist of a magnetic core, which is
coatedwith a polymermaterial that can be derivatized using awide
range of functional groups. Several types have been described in
the literature; some with porous structure to specifically retain
target analytes, for example restricted access materials (RAM)[3,4]
or molecular imprinted polymers (MIP)[5,6]; others with very specific
functional groups (e.g. immunosorbents),[7] or unspecific materials
such as non-polar coatings (C8, C18,…),[8–11] ion exchange
groups,[12–14] ormoieties that provide aromatic interactions. The ex-
traction procedure is similar to solid-phase extraction (SPE); i.e.,
loading, washing, and elution, with the added advantage that the
suspended magnetic beads can be handled as a liquid. These
materials also provide very high extraction efficiencies because of
their large specific surface area per weight compared to packed
SPEmaterials. Possible applications of these sample preparation ap-
proaches include drugs of abuse testing (DAT) or therapeutic drug
monitoring (TDM). Magnetic particles have frequently been used
for extraction and pre-concentration of drugs in complex biological
fluids,[2,9,11,12,15,16] mostly for extraction of highly hydrophobic
analytes using reversed-phasematerials.[2,9,12,17–19] Only a few stud-
ies have reported on the extraction of strongly polar analytes from
biological fluids. Extraction of polar analytes is generally more
challenging than extraction of non-polar substances. Wang et al.
proposed the use of restricted access materials (RAM) for extraction
of polar therapeutic drugs from urine.[3] Efficient extraction was
shown but the approach required long incubation and elution
times because of slow diffusion of analytes in the pores of the
particles. Other groups have applied functionalizedmagnetic beads
to precipitate and remove the matrix components (proteins, lipids,
etc.) from the sample, leaving a clean extract.[17] This approach is
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faster because only a single pipetting step is needed. It has shown
good results for non-polar targets and should also be efficient for
hydrophilic targets. One major disadvantage is the required dilu-
tion of samples during the workflow to support protein precipita-
tion in serum. Because of the organic solvent in the resulting
extract, samples usually have to be further diluted prior to LC-MS
analysis. Strong hydrophilic compounds can also be captured by
implementing extraction materials of high specificity; for example
MIP[5,20–23] or immunospecific sorbents.[7] While these materials
give assays with high sensitivity, the materials are difficult to syn-
thesize and can give template bleeding (MIP).
In this study, magnetic beads were applied to the quantitative
analysis of acetaminophen (APAP), which is a widely used over-
the-counter drug that can have severe toxic side effects in case of
an overdose or long-term abuse.[24] We have recently presented a
LC-MS/MS assay for simultaneous quantification of APAP and other
pharmaceutically relevant substances in human serum and
plasma.[25] That assay was developed for a group of analytes with
broad range of polarities, namely APAP, its metabolites
acetaminophen-glucuronide (APG), -sulfate (APS), -cysteine (APC)
and -mercapturate (APM) as well as phenacetin, p-phenetidine,
imipramine and amitriptyline. The present study extends the previ-
ous work; it describes the application of magnetic hyper-
crosslinked polystyrene (PS) particles to simultaneous extraction
of the above target substances, with the future potential for full
automation of the process. For the method development work, all
instrumental parameters that had the potential to influence the ex-
traction process were carefully optimized. Conventional optimiza-
tion procedures investigate parameters such as temperature, pH,
buffer etc. one by one; that is, one parameter is systematically
varied, while all others are kept constant. That procedure is time-
consuming and, importantly, second order interactions are some-
times overlooked and the optimum extraction efficiency not always
found. By using a software-controlled statistical approach in this
work instead, viz., design of experiments (DoE),[26] the influence of
all parameters (including their second order interactions) were si-
multaneously investigated, resulting in a considerably reduced
number of experiments and the possibility to identify significant
outliers of the measurements.
Experimental
Reagents and chemicals
The USP reference standard for APAP was purchased from LGC
Standards (Wesel, Germany). The metabolites 4-acetamidophenyl
β-D-glucuronide sodium salt (APG), 4-acetaminophen sulfate po-
tassium salt (APS), 3-(N-acetyl-L-cystein-S-yl) acetaminophen so-
dium salt (APM) and 3-cysteinylacetaminophen trifluoroacetic
acid salt (APC) as well as N-acetyl-L-cysteine, p-phenetidine and
phenacetin were purchased from Toronto Research Chemicals (To-
ronto, ON, Canada). Imipramine (1mg/mL in methanol) was from
Cerilliant (Wesel, Germany). Amitriptyline was from Sigma-
Aldrich (Steinheim, Germany). Deuterated analogues of the
analytes were used as internal standards. Imipramine-d3 was ob-
tained from Cerilliant and amitriptyline:HCl (N,N-dimethyl-d6)
from Cambridge Isotope Laboratories (Saarbrücken, Germany)
at 100 μg/mL in methanol. The deuterated substances APAP-
d3, 4-acetamidophenyl β-D-glucuronide-d3 sodium salt (APG-d3),
4-acetaminophen-d3 sulfate (APS-d3), 3-(N-acetyl-L-cystein-S-yl)
acetaminophen sodium salt-d5 (APM-d5), 3-cysteinylacetami-
nophen-d5 trifluoroacetic acid salt (APC-d5), p-phenetidine-d5
hydrochloride, phenacetin-d5 were from Toronto Research
Chemicals. LC-MS grade solvents were from Biosolve (Valkenvaard,
the Netherlands). Formic acid (FA) (98 100%) and Sodium phos-
phate dihydrate were purchased fromMerck (Darmstadt, Germany)
and tris(2-carboxyethyl)phosphine (TCEP) from Sigma-Aldrich.
Human serum pools from Tennessee Blood Services (Memphis,
TN, USA) were used as negative calibrator matrix. Water was gener-
ated using a Waters Millipore Milli-Q-Plus purification system
(Eschborn, Germany).
Extraction beads
Melamine resin particles (MF, diameter 2.15μm) were purchased
from Microparticles GmbH (Berlin, Germany) and native carboxylic
acid coated particles (Dynabeads M-270, diameter 2.8μm) were
from Life Technologies (Thermo Fischer, Bremen, Germany); the
derivatization of the surface with alkylchains was performed
at Roche Diagnostics GmbH (Penzberg, Germany). Polystyrene
micro-particles (diameter ~4 μm) were synthetized by Roche
Diagnostics GmbH. C8/C18 coated magnetic microparticles were
from Agilent Technologies (Böblingen, Germany). The smaller
hyper-crosslinked polystyrene (hcPS) beads exhibited a diameter
range from 25 to 40μm, the larger beads were Dowex Optipore
SD2 from Dow Chemical Company (Amsterdam, the Netherlands)
with a diameter distribution from 160μm to 1mm.
Sample preparation
A graphic scheme of the sample preparation steps is shown in
Figure 1. For each sample, 25μL of serum were mixed with 25μL
of internal standard solution and 400μL of water. After mixing
the samples for at least 20min using a thermomixer, 50μL of TCEP
were added to the mixture and samples mixed for another 30min
at 37°C. Then, 25mg of dry magnetic beads were added to each
sample. The beads were allowed to interact with the samples for
15min under gentle rolling conditions, so that the analytes could
access the entire surface of the particles. The supernatants were
then discarded and the magnetic beads washed with 500μL of
water. The washing solutions were also discarded before elution
with 120μL of acetonitrile/water 70:30 v/v. From the eluate,
100μL were then withdrawn from the vials and diluted 1:3 with
water, before injection into the LC-MS/MS system.
Instrumentation
The chromatographic system consisted of Dionex (Germering,
Germany) U3000 binary pump, column oven and autosampler.
Chromatographic separation was achieved on a Phenomenex
(Aschaffenburg, Germany) Kinetex PFP column (2.6μm, 150 x
3.0mm, 100Å). Gradient elution at a flow rate of 300μL/min was
performed (Table 1). Themobile phase was water+0.1% formic acid
(eluent A), water/ACN 50:50 v/v +0.1% FA (eluent B) and acetonitrile
+0.1% formic acid (eluent C). The total run time of analysis was
19min. The separation column was heated to 40°C during separa-
tion. Two mass spectrometers were used for the described work.
Preliminary experiments were carried out on a Thermo Fisher Scien-
tific (Bremen, Germany) LTQ ion trap equippedwith an electrospray
ionization source (ESI). The final quantification method was then
transferred to a TSQ Vantage triple quadrupole mass spectrometer
(QqQ) equipped with a heated electrospray ionization source
(HESI). Analyses were performed in positive ionization mode. The
ion source parameters were set to the following values: sprayer
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voltage: 4500V (TSQ)/4000V (LTQ), capillary temperature: 250°C
(TSQ)/350°C (LTQ), vaporizer temperature: 350°C (TSQ)/source
heater temperature: 150°C (LTQ), auxiliary gas: 10psi (TSQ)/8 psi
(LTQ), sheath gas 30psi (TSQ)/28 psi (LTQ). Nitrogen was used as
sheath and auxiliary gas. The argon pressure in the collision cell
was 1.0 mTorr. MRM transitions and optimized collision energies
(CE) for each transition are summarized in Table 2.
Performance data
The analytical performance of the method was investigated by de-
termining precision and accuracy, as well as linearity, recovery and
specificity. The regression model used was linear with 1/X
weighting. Linearity was ensured for the analytes with a regression
parameter R2> 0.99. Precision was determined using three spiked
serum samples with concentrations ranging from 1.5 to 25μg/mL,
depending on the analyte. Each sample was processed and ana-
lyzed six times; the coefficient of variation (CV) was calculated for
the mean of all six preparations. To assess the accuracy of the
method, a set of patient samples was measured and compared to
the results obtained with a previously described and fully validated
LC-MS method (see below). Recovery for all analytes was deter-
mined by comparisonwith peak areas of corresponding deuterated
internal standards in duplicate from eight calibrator samples. The
mean over the 16 values was calculated for each fraction of the
workflow: wash steps 1, 2 and 3, and eluate. The recovery was cal-
culated by comparing the amount of substance found in each frac-
tion to the sum of all fractions. Specificity was verified by analyzing
two different pools of analyte-free serum samples purchased from
Tennessee Blood Services. Additionally, ion suppression from
glycerophosphocholines (GPCho) was assessed by monitoring
common fragments to all GPChos in SIMmode over the entire chro-
matographic run. By applying a high declustering voltage (40 V) in
the ionization source of the mass spectrometer, GPChos readily
undergo in-source collision-induced dissociation (CID) and form
the product ion trimethylammonium-ethylphosphate (m/z 184)
that can further dissociate to trimethylammoniumethylate (m/z
104).[27] Stability of the samples had already been assessed in our
previous work;[25] these experiments were therefore not repeated.
Quantification
Calibrators were prepared in human serum (Tennessee Blood Ser-
vices). Each batchwas tested before preparing calibrators, to ensure
that it contained no traces of target analytes. An aqueous stock so-
lution of all analytes was diluted in serum to obtain 8 calibrator
levels. The calibration ranges were different for all analytes. APAP,
APG, p-phenetidine and phenacetin were measured between 0.1
Figure 1. Sample preparation steps using magnetic particles.
Table 2. MRM transitions and applied collision energies for all investigated substances and their corresponding internal standards. Values correspond to
settings for QqQ instrument (parameters shown in italics were used for ion trap experiments)
Analyte MRM transition CE [V] ISTD MRM transition CE [V]
APAP m/z 152.1➔110.0, 65.0 25, 15 APAP-d3 m/z 155.1➔111.1, 65.0 25
m/z 152➔ 110 28 m/z 155➔ 111 28
APG m/z 328.1➔ 151.9 18 APG-d3 m/z 331.0➔ 154.8 18
m/z 328➔ 152 28 m/z 331➔ 155 27
APS m/z 231.9➔151.9, 109.9 18 APS-d3 m/z 234.9➔154.9, 110.9 18
APM m/z 313.1➔207.9,165.8 20 APM-d5 m/z 318.1➔212.0, 167.8 20
APC m/z 271.0➔182.0, 140.0 18 APC-d5 m/z 276.1➔186.7, 142.9 18
p-Phenetidine m/z 138.1➔110.0, 93.0 20 p-Phenetidine-d5 m/z 143.1➔111.0, 93.0 18
Phenacetin m/z 180.0➔138.1, 110.0 22 Phenacetin-d5 m/z 185.1➔143.1, 111.0 18
Imipramine m/z 281.2➔ 86.0, 58.0 25 Imipramine-d3 m/z 284.2➔89.1, 61.1 25
Amitriptyline m/z 278.2➔233.1, 90.9 20 Amitriptyline-d6 m/z 284.3➔233.1, 91.0 25
m/z 278➔ 233 28 m/z 284➔ 233 28
Table 1. Eluent gradient composition
Time [min] % Eluent B % Eluent C
0 0 0
6 50 0
13 0 100
16 0 100
16.1 0 0
19 0 0
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and 100μg/mL, APS between 0.03 and 50μg/mL and APM, APC,
imipramine and amitriptyline between 0.01 and 10μg/mL. Internal
standard concentrations are summarized in Table 3. All compounds
were quantified by LC-MS/MS using multiple reaction monitoring
(MRM). Calibration curves were constructed using analyte/internal
standard peak area ratios. Unknown samples were quantified by
comparing the ratio of the integrated area of the analyte and the
corresponding internal standard to the calibration curve.
Accuracy
To evaluate performance and accuracy of the new extraction
method, 68 patient samples were analyzed and values compared
to results obtained for the same samples using a previously
established LC-MSmethod,[25] which also lists information on ethics
approval of the study. This experiment was conducted for the main
target APAP as well as for themetabolites APG, APS, APC, and APM.
Regression was performed using Passing-Bablok analysis.
Statistical analyses
Statistical analysis was carried out using the software JMP (SAS,
Böblingen, Germany). For DoE, the user can chose screening or re-
sponse surface designs, resembling qualitative or quantitative anal-
yses, respectively. Screening designs are used to investigate a large
number of experimental parameters using a minimized number of
runs, providing information on the influence of each factor as well
as some second-order factor interactions. Response surface designs
aim at the optimization of the value of defined experimental pa-
rameters. These experimental parameters are described as factors
in the DoE process that are divided into three categories. Firstly,
continuous factors can take any value in a given interval; they are
represented by continuous numbers (e.g. temperature, pH,
volume…). Secondly, discrete factors only have particular values,
but are not necessarily numeric (e.g.number of wash steps, type
of magnetic particle…), and finally, Boolean factors are discrete
factors that exhibit only 2 levels (yes or no). After the nature of
the responsewas chosen (e.g.peak area of analyte in eluate fraction
of the extraction procedure), a number of factors suspected of
having an influence on this response were listed and their effect
studied between two user-defined limits. The software generated
a number of experiments that were conducted in a randomized
order to avoid systematic errors. Analysis of results was then per-
formed; a general regression model set up and optimized to fit
the experimental data. Outliers were identified by the software
and marked, to avoid misinterpretation of the data.
Results and discussion
Prior to the method optimization experiments, all parameters
known or suspected to influence the extraction process were listed
in the fishbone diagram shown in Figure 2. For the DoE software
(see Experimental), two different screening designs were created.
While this approach substantially reduced the number of required
experiments, it did not jeopardize any analytical input information
needed for determining the significance of the factors and their in-
teractions. DoE approaches have been successfully applied in assay
development.[28–30] Chromatographic separation of the analyte
panel was performed as previously described.[25]
Development and optimization of the method
Screening design 1
For the first screening design, several types ofmagnetic beadswere
evaluated for extraction of three of the target analytes: APAP, APG,
and amitriptyline. Since the main difficulty of the extraction proce-
dure was simultaneous extraction of analytes with a wide range of
polarities, these three analytes were chosen because they span the
entire range of polarities within the target analyte panel: APG is the
most polar compound; amitriptyline is non-polar and APAP is a ‘me-
dium’ polarity analyte. Several types of bead chemistries were
tested, including C8/C18 saturated carbon chains for hydrophobic
interactions, ion exchangers (carboxylic acid as cation and mela-
mine as anion exchanger), polystyrene as well as 25-40μm diame-
ter hyper-crosslinked polystyrene for π-π interactions. Depending
on the chemical nature of the extraction material, several factors
that potentially influence adsorption and desorption of the target
analytes such as pH, temperature, type of organic solvent etc. were
tested in this design, which are marked in blue in the fishbone dia-
gram in Figure 2. Particle (C8/C18, MF, hcPS or PS) and eluent type
(acetonitrile, methanol or iso-propanol) were set as discrete factors.
All other tested factors were continuous. Incubation pH was varied
between 5 and 9 and incubation temperature was set to 4, 20, and
37°C, incubation time ranged from 5 to 55min. The elution pH was
also tested between 5 and 9 (depending on the pKa of the surface
groups on the beads), elution volume was varied from 30 to 90μL,
and the percentage of organic solvent in the elution solution was
investigated between 20 and 80%. All other factors were kept con-
stant. Ninety experiments were necessary for this screening design.
The response was defined as the presence of a peak in the resulting
chromatogram. Aqueous solutions of the target analytes at a con-
centration of 100μg/mL were used. Five mg of particles suspended
in 100μL of 0.1M phosphate buffer at pH7 were added to 10μL of
sample. Different times and temperatures were tested for the incu-
bation step of analyte and particles. Following incubation, the par-
ticles were washed twice with 200μL buffer. The wash solutions
were discarded. Eluates were collected after 10min of incubation
with the particles and measured via LC-MS/MS.
Screening design 2
The second screening design was aimed at the investigation of ef-
fects of polarity of themagnetic bead surface on extraction of polar
substances. For this purpose, micro-particles carrying carboxylic
acid groups were modified with different amounts of aliphatic C8
chains. They were used to test the efficacy of extracting the three
model target substances. Four different batches were compared:
the original unmodified beads (D-0x), and batches modified with
25-fold (D-25x), 100-fold (D-100x), and 300-fold (D-300x) excess of
Table 3. Concentration of internal standard in samples
ISTD Conc. [μg/mL] Used for
APAP-d3 1.03 APAP
APG-d3 0.85 APG
APS-d3 1.57 APS
APM-d5 9.06 APM
APC-d5 6.55 APC
Phenacetin-d5 7.53 Phenacetin
p-Phenetidin-d5 7.67 p-Phenetidin
Imipramin-d3 7.53 Imipramin
Amitriptylin-d6 7.67 Amitryptilin
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octyl amine. Additionally, other factors were included in the second
screening design; they are marked in orange in Figure 2. They in-
clude particle type (discrete factor) and type of additive used prior
to sample extraction and heating of the sample during incubation.
The additive was defined as a continuous factor, where pure etha-
nol and t-butanol defined the limiting points and ethanol:t-butanol
at 1:1 ratio served as center point. The response was defined as the
recovery of the target substance in the elution fraction. The test sys-
tem consisted of aqueous and serum samples containing approx.
12μg/mL of the three target substances. Heating the samples to
60°C was also set as a continuous factor and was performed for 0,
10, and 20min. The percentage of additive (water, ethanol or t-
butanol) was tested at 0, 30, and 60% and the amount of particles
added to the samples was 1, 1.5, and 2w/v, corresponding to 0.5,
0.75, and 1.0mg dry particles, respectively. Twenty microliters of
aqueous solutions containing all three analytes at a concentration
of approx. 10μg/mL were used for each extraction.
Result screening design 1
The measurements for screening design 1 were carried out using
an ion trap MS and statistically analyzed using DoE software (see
Experimental). The following parameters exhibited a significant in-
fluence on the target response: particle type, type of organic eluent
and percentage of organic solvent in the elution solution. Other fac-
tors did not influence the extraction efficiency of the target analytes
significantly. Acetonitrile showed higher recoveries than methanol
and iso-propanol, and a minimum of 65% acetonitrile was needed
for elution of the target substances. Since the incubation pH was
not a significant factor, the samples were dilutedwith water instead
of buffer in subsequent experiments. Incubating for longer than
5min did not show any further improvements of sensitivity. The ob-
servations regarding pH and equilibration time differed from previ-
ous results for extraction of highly hydrophobic compounds
(antidepressants, phenolic compounds) using magnetic particles
coated with ionic surfactants,[12,18,19] where pH and equilibration
times exhibited significant influence on sample preparation. That
influence was probably due to variations of adsorption of the highly
hydrophobic drugs on the rather labile surface of hemimicelles
formed by ionic surfactants as compared to the static and stable
surface of the polystyrene particles used here. A further important
observation from this screening design was that APG was very diffi-
cult to extract using functionalized magnetic beads as compared to
the other target analytes. The recoveries in the eluate fractions for
this substance were virtually zero in almost all preparations, except
when using hyper-crosslinked polystyrene (hcPS) particles.
Extraction of amitriptyline and acetaminophen could be achieved
with hydrophobic particles, anion exchangers and hyper-crosslinked
polystyrene particles.
Result screening design 2
The beads tested in the second screening design were derivatized
with octyl chains to obtain mixed-mode extraction surfaces. The
polarity of the four batches of magnetic beads D-0x, D-25x, D-
100x, and D-300x decreased with increasing number of octyl chains
bound to the surface. It was assumed that the combination of polar
groups and non-polar alkyl chains would allow extraction of both
hydrophilic and hydrophobic target analytes. Unfortunately, the
representative substance for polar analytes, APG, was not extracted
with any of the tested particles, under none of the tested condi-
tions. In fact, the type of particle and the amount of particles per
sample were marked as non-significant by the DoE software. The
extraction efficiency of the original particles for APAP and amitripty-
line was similar to the derivatized versions but the obtained peak
areas for APAP were all very small, making these magnetic beads
not suitable for the application. The solvents added to the samples
prior to the extraction were assumed to favor the adsorption of po-
lar analytes to the surface of the beads by decreasing the polarity of
the liquid phase. Instead, a significant decrease in intensity of the
target response was observed for the medium and non-polar
analytes APAP and amitriptyline. The high percentage of organic
solvent appeared to inhibit the adsorption of hydrophobic analytes
to the magnetic beads without showing any improvement for the
extraction of hydrophobic targets. Heating to 60°C during incuba-
tion with the particles also showed a negative effect on the recov-
ery of the particles.
The two described screening designs allowed us to identify all
relevant factors that exhibited strong influence on the outcome
of the new sample preparationmethod. Unfortunately, the simulta-
neous extraction of the three target substances was difficult with
most materials and only one of the eight tested particle types
allowed simultaneous extraction of APAP, APG, and amitriptyline.
The following experiments were therefore limited to hyper-
crosslinked polystyrene particles. Factors that showed a significant
effect were the type and percentage of organic eluent for elution,
type and percentage of additive to samples prior to the extraction,
as well as temperature for equilibration of the samples with the
beads. Non-significant parameters for this sample preparation were
sample pH, equilibration time with the particles, eluent volume and
pH, elution time and degree of derivatization in case of modified
Dynabeads particles. An amount of 0.5mg of particles was
Figure 2. Fishbone diagram representing the investigated parameters related to the sample preparation protocol.
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sufficient for extraction of the target substances. This amount de-
pends on the size of the beads and has to be adjusted when larger
particles are used.
Additional experiments were carried out to optimize the sensitiv-
ity of the method, without experimental design considerations. The
relevance of the size of the particles was investigated by comparing
hcPS particles (diameter 25-40μm, non-magnetic) with larger
beads (Optipore SD 2, diameter distribution 0.1-1mm, magnetic).
Considering the largest particles of each batch, the differences in di-
ameters between both types corresponded to a factor of 500. As-
suming that both types of beads have the same density, the
specific surface area available per mg dry particles then decreased
by a factor of almost 20. Since 0.5mg small hcPS particles were suf-
ficient for extraction of 20μL of sample, this meant that at least
10mg of the larger particles were needed for extraction of the same
amount of compound. Considering that the larger particles
(Optipore) have a higher density because of their magnetic core,
the amount was further increased to 25mg for extraction of each
sample, to insure that enough binding sites are available for all tar-
get substances. In order to determine the absolute recovery of sam-
ple preparation with both bead sizes, a spiked solution containing
20ng of analyte was processed with both particle types, using the
optimized protocol obtained after both screening designs. Addi-
tionally, an external calibration curve was performed with aqueous
solutions containing all three test analytes. No internal standard
was used for these experiments. The recorded peak areas in the el-
uate fraction were compared to the calibration curve to determine
the amount of target substance. The obtained value was divided by
the initially spiked concentration to obtain the absolute recovery of
the sample preparation step. The smaller beads yielded a recovery
of 63% for APAP, >100% for APG and 25% for amitriptyline; the
larger particles showed recoveries of 53% for APAP, 100% for APG
and 49% for amitriptyline. Since no internal standard was used for
these measurements, the imprecision of the results was high, espe-
cially for APG, which showed smaller response surface areas than
the other analytes. This effect readily explains the over-recovery of
APG seenwith the first set of particles. No significant increase of sen-
sitivity was provided by using the larger particles, but since they
showed amore uniformdistribution of recoveries for the three types
of polarities, they were chosen for the sample preparation protocol.
Transfer to complete panel of target substances
The next step was the transfer of the developed protocol to the en-
tire panel of target substances. Serum samples containing all nine
analytes were processed using the large hcPS particles. The opti-
mized parameters from both screening designs were used in these
experiments. The percentage of organic solvent in the elution step
was determined by testing three water/ACN ratios. Results from the
first screening design indicated that a minimum of 65% ACN was
necessary for the complete elution of the target substances. The
tested solutions were 60, 70, and 80% ACN in water. An increase
in the signal intensities was observed between 60 and 70% ACN,
but no clear benefit was seen for 80% ACN. Additionally, the peaks
for the polar analytes eluting at the beginning of the chromato-
graphic run showed significant tailing for 80% ACN during elution
because retention on the column was strongly affected by the
higher content of organic solvent. Larger dilution of the eluate prior
to the injection would result in a loss of sensitivity; therefore, 70%
ACN was chosen. The final protocol was transferred to the QqQ in-
strument for all further analyses. Two MRM transitions were imple-
mented per analyte, because of the faster acquisition rates of QqQ
versus ion trap. A volume of 25μL serum sample as previously
implemented[25] was first diluted with water and then reducedwith
50μL of a 350mmol/L tris(2- carboxyethyl)phosphine (TCEP) solu-
tion under heating conditions at 37°C for 30min, before adding
25mg of dried magnetic particles. The mixture was allowed to
equilibrate for 15min. The washing step was performed with water
before elution with 120μL 70% ACN; 100μL eluate was diluted 1:3
with water before injection into the LC-MS/MS system.
Reduction using TCEP was initially incorporated for detection of
the antidote of acetaminophen, N-acetyl-L-cysteine (NAC). NAC
strongly binds to serum proteins, by forming disulfide bonds that
have to be reduced before the antidote can be detected. Good re-
sults for release of NAC from the serum proteins have previously
been observed using TCEP;[25] therefore, this step was incorporated
in the sample preparation protocol without further optimization.
NAC was very difficult to ionize using ESI, but showed slightly
better efficiency in negative versus positive ionization mode. Initial
experiments using the ion trap mass spectrometer did not provide
sufficient sensitivity for quantification of NAC at the desired
concentration levels, which did not allow us to verify whether the
described sample preparation method can also be used for this
substance. NAC was omitted from the following experiments.
Performance of the method
The performance of the new sample preparation method was
assessed by determining the linearity, precision and recovery of the
assay. Possible ion suppression effects from glycerophosphocholines
(GPCho) were also investigated and compared to a clean-up proce-
dure based on dilution and filtration of the samples. Sixty-eight na-
tive serum samples were used to carry out a method comparison
with both sample preparation methods.
Linearity
To assess linearity, the regression coefficients were determined for
all analytes in the concentration ranges described in the Experi-
mental section. An eight-point calibration was carried out; the ob-
tained regression equations as well as R2 values are summarized
in Table 4. APS exhibited the lowest value for R2, which was due
to the lower detection sensitivity for this analyte. APS is one of
the most polar substances in the chosen analyte panel; therefore
the affinity to the extraction phase was not as high as for non-polar
substances. The peak areas were therefore much smaller and more
prone to variations within the analytical system. Nevertheless, all
values for R2 were higher than our cut-off level set at 0.99. The
method was therefore linear in the chose calibration ranges for all
analyzed target substances.
Precision
Precision was determined using three spiked serum samples at
three concentration levels. The concentrations of the analytes in
each level as well as calculated CVs are indicated in Table 5. Each
sample was processed and analyzed 6 times. Level 2 was analyzed
in duplicate; both injections were averaged before calculation of
the precision. Level 1 and 3 were only injected once into the LC-
MS/MS system. The CVs were calculated for themean of all 6 values.
The calculated CVs ranged from 2% to 9%. The highest impreci-
sion was obtained for APG and APS, which was due to the low de-
tection sensitivity. This was expected, since these are the two most
polar substances of the analyte panel and the method exhibited
decreased efficiency for increasing polarity. No useful data was
obtained for APS for levels 2 and 3, because of a mishandling of
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the samples. Overall, the performance of the presented assay was
comparable to other published methods for extraction of pharma-
ceutically relevant compounds from biofluids.[2,9,12,17–19]
Ion suppression
Compounds known to cause strong ion suppression in ESI-MS are
glycerophosphocholines (GPCho).[31,32] Their influence was
assessed by processing and injecting analyte-free serum into the
LC-MS/MS system, as described in the Experimental section.
Chromatograms for magnetic beads were compared to chromato-
grams obtained using the previously published LC-MS/MS
method[25] (Figure 3). The profiles were very similar; the intensities
for the two recorded m/z traces started to increase at ca. 12-
13min. The maximum intensity was reached at the end of the anal-
ysis, during the wash step of the gradient. Since the last analyte
(amitriptyline) eluted from the column after 15min, this experiment
confirmed that the sample matrix did not interfere with the analy-
sis. Comparison with the elution profile of the previousmethod also
showed that extraction with magnetic particles did not improve on
the elimination of phospholipids from the samples. Since no pro-
tein precipitation step was carried out prior to the extraction,
GPChos were very abundant in the sample when the magnetic
beads were added. They appear to have similar affinity to the ex-
traction phase than the analytes, since they are highly recovered
during the elution phase. Since GPChos were chromatographically
separated from the target substances, their presence in the elution
fraction did not pose a problem for this application.
Recovery
The recovery of the method was investigated by determining the
distribution of the analytes over the entire workflow. For these ex-
periments, threewashing steps were carried out. The concentration
of each target analyte was then determined in each of the four frac-
tions: wash step 1, 2, and 3 and eluate. The supernatant of the first
step could not be injected directly into the LC-MS/MS instrument,
because of the high concentration of matrix components that
would lead to a severe contamination of the ionization source.
The results of this experiment are summarized in Table 6. The per-
centages shown correspond to the amount of substance found in
each fraction compared to the sum of all fractions. This data shows
clearly that only the first wash step had a significant influence on
analyte recovery. APG, APS and APC were significantly represented
in the first wash solution. Only 0-4% analyte were contained in the
wash fractions 2 and 3. This confirms that one wash step was suffi-
cient to remove components that were loosely (or not at all) bound
to the magnetic beads. Another obvious effect was the clear rela-
tion between percentage of analyte found in the eluate fraction
and its polarity. Non-polar analytes were more effectively retained
than polar analytes. The relationship between log P values and
amount found in the eluate fraction is shown in Table 6. The
analytes are classified by decreasing polarity and their distribution
in the four analyzed fractions is graphically displayed in Figure 4.
Table 5. Coefficients of variation calculated for 3 spiked serum samples
at different concentrations with n=6 preparations (except for imipra-
mine and amitriptyline at Level 2)
Analyte Level 1 Level 2 Level 3
[μg/mL] CV [μg/mL] CV [μg/mL] CV
APAP 30 4% 17.4 2% 1.0 3%
APG 30 9% 17.2 2% 1.0 2%
APS 15 n.z. 8.1 7% 0.5 n.z.
APC 3.0 3% 1.7 3% 0.1 2%
APM 3.0 3% 1.7 3% 0.1 2%
p-Phenetidin 30 3% 17.4 5% 1.0 3%
Phenacetin 30 8% 16.8 2% 1.0 3%
Imipramin 3.0 6% (n=5) 1.7 3% 0.1 4%
Amitriptylin 3.0 5% (n=4) 1.7 2% 0.1 4%
Table 4. Regression curves for the analytes and corresponding coeffi-
cients of regression (R2)
Analyte Regression curve R2
APAP y=0.032x+0.009 0.9983
APG y=0.0186x+0.0016 0.9965
APS y=0.1808x - 0.0520 0.9911
APC y=0.6743x - 0.0045 0.9970
APM y=0.4963x+0.0124 0.9977
p-Phenetidin y=0.09224x+0.0010 0.9968
Phenacetin y=0.1453x+0.0085 0.9994
Imipramin y=0.3511x - 0.0009 0.9993
Amitriptylin y=0.6417x+0.0004 0.9991
Figure 3. Extracted ion chromatograms using GPCho’s in-source dissociation products (m/z 104 and 184) for two sample preparation methods: (a) dilution
and filtration, and (b) extraction with magnetic beads.
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Apart from APM,which behaved differently than expected from the
log P value, the percentage found in the eluate fraction increased
with increasing log P. Since a large error range is given for calcu-
lated log P value of APM, it is possible that this compound also fits
the overall trend well.
Method accuracy, analysis of patient samples
The accuracy was evaluated by measuring 68 patient samples that
had previously been analyzed using an established, fully validated
LC-MS/MS method.[25] The obtained values for the main target
APAP and formetabolites APG, APS, APM, and APC were compared.
Unfortunately, no comparison was possible for the other analytes,
since they are not metabolites of the main target but structurally
similar components that could influence the result of the immuno-
assay. Their quantification in patient samples was therefore not
seen as critical as the main target or its degradation products; no
sample collection was performed for these compounds.
The result of the comparison for APAP is shown in Figure 5. The
Passing-Bablok regression analysis gave very good correlation for
both methods. Similar results were obtained for the metabolites;
their correlationwith the referencemethod for APAP is summarized
in Table 7. Some samples exhibited metabolite concentrations
below the LLOQ of the method; metabolite concentrations could
therefore not be determined in all 68 patient samples. It was obvi-
ous from the data that the measured values correlated better for
lower concentration values. This was due to the fact that samples
outside the calibration range (>100μg/mL) had to be diluted with
analyte-free serum prior to sample clean-up. Since this step was not
compensated by the internal standard, a higher imprecision was
expected for samples with a higher concentration than the highest
calibrator (>100μg/mL for APAP). Nevertheless, the correlation be-
tween both methods was still excellent.
To our knowledge, this work is the first to describe a generic
method for simultaneous extraction of nine different target
analytes from human serum using reversed-phase magnetic
Table 6. Recovery of the target compounds in each step of the
workflow and log P valuesa
Analyte Recovery Log P
Wash
step 1
Wash
step 2
Wash
step 3
Eluate
APAP 7% 3% 2% 87% 0.475 (±0.201)
APG 25% 4% 2% 68% 1.811 (±0.434)
APS 28% 1% 0% 71% 0.146 (±0.417)
APC 14% 7% 4% 75% 0.451 (±1.035)
APM 5% 0% 0% 95% 0.575 (±1.043)
p-Phenetidine 6% 4% 4% 87% 1.445 (±0.219)
Phenacetin 2% 1% 0% 97% 1.655 (±0.222)
Imipramine 2% 0% 1% 97% 4.355 (±0.302)
Amitriptyline 1% 0% 1% 98% 4.41 (±0.266)
aSource: SciFinder, calculated using Advanced Chemistry Development
(ACD/Labs) Software V11.02.
Table 7. Correlation of obtained results with magnetic particles
sample preparation compared to the established reference
method
Metabolite Correlation to Ref.[25] Sample number
APG y=1.03x – 0.29 60
APS y=1.03x – 0.40 59
APC y=1.05x – 0.01 61
APM y=1.06x+0.00 61
Figure 4. Graphic representation of the distribution of the target analytes in the analyzed fractions, in order of decreasing polarity.
Figure 5. Comparison of the obtained values for APAP in 68 patient
samples using the described sample preparation method in the present
study and an established LC-MS/MS method.
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particles. Because of the possibility for full automation, this method
competes with online extraction methods such as RAM or
Turboflow extraction.[33–39] The performance data shown here are
generally comparable to Turboflow extractions; only few Turboflow
assays have shown slightly better sensitivity[33] but required large
volumes of organic solvent volumes and high eluent flow rates.
Also, high carry-over effects were seen in those studies with little
effect on phospholipid removal.[40,41]
Conclusion
The aim of the present work was the development of an im-
proved sample preparation method for acetaminophen and its
main metabolites, structurally related drugs, and the tricyclic an-
tidepressants imipramine and amitriptyline in a complex biolog-
ical matrix using magnetic particles. The experiments were
planned using a design of experiment (DoE) statistical approach
with three representatives analytes (APG, APAP, and amitripty-
line), which covered the entire span of chemical polarities of
the analyte panel. Generally, it was observed that extraction of
the strongly polar analyte APG was more challenging than less
polar analytes. Only one of the tested particle types allowed
simultaneous extraction of the three model analytes and was
used for analysis of the entire panel of targets substances. The
new assay was compared to an established and validated LC-
MS/MS reference method and showed very good correlation of
the results for a collective of 68 native serum samples for APAP
as well as its metabolites.
Overall, the extraction with magnetic beads resulted in a consid-
erable decrease of time needed for sample preparation as com-
pared to the dilution and filtration clean-up approach described
previously. Particle suspensions can be handled as liquids, allowing
full automation of the sample preparation process. Moreover,
smaller sample volumes can be used as compared to e.g. solid-
phase or liquid-liquid extraction, because of the high specific sur-
face of the beads. The described method is fast and simple, and
can be applied to simultaneous extraction of analytes with a wide
range of chemical polarities, making the extension of the described
assay to other target substances readily possible. Magnetic beads
also permit enrichment of matrix components such as proteins
and lipids; to remove them from the sample or for analysis. Chem-
ical modifications of the surface of the magnetic beads allow them
to be adapted to many applications including DAT/TDM analyses,
proteomics, waste water analysis etc.
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Simultaneous quantification of digoxin,
digitoxin, and their metabolites in serum
using high performance liquid chromatography-
tandem mass spectrometry
Caroline Bylda,a,b Roland Thiele,a Uwe Kobolda and Dietrich A. Volmerb*
The aim of this work was the development of a liquid chromatography-tandemmass spectrometry (LC-MS/MS) method for simul-
taneous quantification of two cardiac glycosidic drugs in human serum, namely digoxin (DG) and digitoxin (DT), as well as several
of their metabolites: digoxin-bis-digitoxose and digoxin-mono-digitoxose, digitoxin-bis-digitoxose and digitoxin-mono-
digitoxose, digoxigenin, digitoxigenin, dihydrodigoxin and acetyl- and methyldigoxin. The assay also allowed for semi-
quantitative analysis of two structurally similar compounds, deslanoside and lanatoside. As internal standards, deuterated analogues
were synthesized for some of the target analytes. Highly abundant proteinswere initially removed by protein precipitation using zinc
sulfate before samples were extracted by supported liquid extraction. Chromatographic separation was achieved on a
pentafluorphenyl stationary phase prior to electrospray ionization triple quadrupolemass spectrometry inmultiple reactionmonitor-
ing mode. The assay allowed quantification of the analytes with lower limits of quantification between 0.04 and 2.0 ng/mL. Linearity
was shown over the range 0.16–9.5 ng/mL for DG and its metabolites, and 1.6–95 ng/mL for DT and its metabolites with correlation
coefficients R>0.991. The quantification range was determined as 1.1–8.9 ng/mL for DG and its metabolites and 12–90 ng/mL for DT
and its metabolites. Within this range, DG and DT were determined with an accuracy of ±2% and precision <7% RSD. Trueness was
confirmed by analyzing native samples and comparing the results to values obtained by a certified analysis laboratory. In conclusion,
the assay represents a useful reference method for immunoassay-based digoxin and digitoxin tests, which are easily biased by the
presence of metabolites of the target analytes or structurally similar substances. Copyright © 2015 John Wiley & Sons, Ltd.
Additional supporting info may be found in the online version of this article at the publisher’s web site.
Keywords: digoxin; digitoxin; sample preparation; LC-MS/MS
Introduction
Digoxin (DG) and digitoxin (DT) are cardiac glycosides used for
treatment of congestive heart failure and arrhythmias.[1,2] In
addition, recent studies have shown promising effects of these
drugs in the treatment of various cancers.[3–6] Since the therapeutic
range of the substances is very narrow, intoxications from
overdoses of these drugs are not uncommon.[7] Digoxin is the most
frequently used cardiac glycoside;[8] digitoxin and other compounds
such as methyldigoxin (MetDG), acetyldigoxin (AcDG), deslanoside
or lanatoside C are also available for treatment. The absorption
rate, pharmacokinetics and dosage of these drugs strongly differ
from each other,[7] which makes it critically important to have
reliable assays to monitor their levels.[9]
The metabolic degradations of digoxin and digitoxin are shown
in Figure 1.[7] Even though their metabolisms appear to be similar,
major differences with regards to toxicity have been observed
between the two substances. These differences are related to the
excretion route. After oral intake, digoxin undergoes extensive
distribution in tissues and is mainly excreted as unchanged drug
via the renal route;[10] small amounts of its cardioactive metabolites
can also be found in urine. On the other hand, digitoxin is metabo-
lized mainly in the liver rather than the kidneys as seen for digoxin.
For this reason, digitoxin is preferably used in older patients or
patients with renal failure.[11] Major differences are also observed
for the binding affinity of digoxin and digitoxin to serum
proteins,[12] ranging from 92–98% values for DT and its metabolites,
but only 13–21% for DG and its metabolites. These numbers are im-
portant because tissue uptake is related to the free drug concentra-
tion, but not to the total drug concentration.[13] Digoxin is usually
administered to generate serum concentration levels between 0.5
and 2 ng/mL,[14,15] digitoxin between 10 and 25 ng/mL.[16] Appro-
priate cut-off levels for digoxin and digitoxin monitoring assays
are therefore at 2 and 25 ng/mL, respectively.
In addition to digoxin and digitoxin, several other cardiac glyco-
sides are used for treatment. For example, methyldigoxin, which is
eliminated via the renal route; 25% of the given dose is found un-
changed in urine and 30% is metabolized to digoxin.[17] It is also
found unchanged and demethylated in blood.[17] Lanatoside is also
mainly metabolized via the renal route. It shows a poor absorption
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rate when taken orally and is found as deslanoside (80%) and
digoxin (17%) in urine.[7] Acetyldigoxin is used to enhance the
resorption in the intestinal tract. After oral intake, it is quickly
deacetylated and undergoes the same metabolism as digoxin.[18]
In human blood, digoxin is found either after administration of
the drug or as metabolite of deslanoside, digitoxin, acetyldigoxin,
lanatoside C and methyldigoxin.[17,19]
The work presented here was aimed at the development of a sen-
sitive assay for simultaneous quantification of digoxin, digitoxin, their
metabolites digoxin-bis-digitoxose and digoxin-mono-digitoxose
(DGbis and DGmono), digitoxin-bis-digitoxose and digitoxin-mono-
digitoxose (DTbis and DTmono), digoxigenin (DGenin) and digitoxi-
genin (DTenin), dihydrodigoxin (H2DG) and acetyldigoxin and
methyldigoxin in human serum and plasma, to be used as a refer-
ence method for both a digoxin- and a digitoxin-specific immunoas-
say. Additionally, the method was also directed at semi-quantitative
analysis of deslanoside and lanatoside. Several individual liquid
chromatography-mass spectrometry (LC-MS) assays for digoxin
and digitoxin[20–30] have been reported as well as in combination
with their metabolites or related cardiac glycosides.[19,31–35] To our
knowledge, no LC-MS/MS method has been described for simulta-
neous quantification of the above combination of drugs and their
metabolites.
Experimental
Materials, reagents, and chemicals
Digoxin (DG), digitoxin (DT) and β-acetyldigoxin (AcDG) were
purchased from European Pharmacopeia Reference Standards
(Strasbourg, France). Metabolites digitoxin- (DTbis, DTmono) and
digoxin-bis- and –mono-digitoxose (DGbis, DGmono), as well as
digoxigenin (DGenin) and dihydrodigoxin (H2DG) were old stocks
from Boehringer Mannheim (Mannheim, Germany). Methyldigoxin
(MetDG) was from Serva (Heidelberg, Germany); digitoxigenin
(DTenin) and lanatoside from Sigma-Aldrich (Steinheim, Germany).
Deslanoside was an USP Reference Standard. LC-MS grade
solvents (methanol and acetonitrile) were purchased from
Biosolve (Valkenvaard, the Netherlands). Dichloromethane (DCM),
ethylacetate, lithium formate, methyl-tert-butylether (MTBE),
2-propanol (IPA), N,N-dimethylformamid (DMF), deuterium
oxide and methanol-d6 were from Sigma-Aldrich, chloroform
(CHL) from Fisher Scientific (Schwerte, Germany), and triethylamine
and formic acid from Merck (Darmstadt, Germany). Heptane and
zinc sulfate were purchased from Fluka (Buchs, Switzerland).
Human serum from Tennessee Blood Services (Memphis, TN,
USA) was used as a negative calibrator matrix. Lyophilized serum
samples from a round robin trial were obtained from the
Referenzinstitut für Bioanalytik (RfB, Bonn, Germany) and used as
quality control samples. Supported liquid extraction (SLE) car-
tridges Extrelut NT1 were from Merck (Darmstadt, Germany).
Purified water was generated using a Waters Millipore Milli-Q-Plus
purification system (Eschborn, Germany).
Synthesis of deuterated analogues
We adapted the deuteration protocol based on a procedure
described in the literature.[21,36] Briefly, DG and its metabolites
DGbis, DGmono and DGenin were deuterated simultaneously; DT,
DTbis, DTmono and DTenin were labelled in a second batch. The
substances were weighed in a reaction flask and dissolved in
DMF. Four mL of DMF were used per 10 mg of substance.
Figure 1. Metabolic pathway of digoxin and digitoxin.
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Deuterium oxide (1.2 mL) and triethylamine (200 μL) were added
and the mixture was allowed to react for 24 h at 70–80°C under
N2 atmosphere. The reaction mixture was then evaporated to dry-
ness at 70°C under a stream of N2. The dry residue was weighed,
dissolved in deuterated methanol to give a concentration of ~1
mg/mL, and stored at 2–8°C. Characterization was performed by
LC-MS and LC-MS/MS.
Sample preparation
A serum volume of 300 μL was used for each analysis. Eighty μL of a
solution of the eight deuterated compounds were added to the
samples and equilibrated at room temperature for 30 min while
shaking on a thermomixer. Protein precipitation was then carried
out using 700 μL of a ZnSO4 solution (10% w/v). After mixing for
5 min, the samples were centrifuged for 15 min and supernatants
extracted using SLE. After equilibrating the serum extracts on
the SLE support for 10 min, 1 mL of dichloromethane (DCM)/
isopropanol (IPA; 90:10 v/v; elution solvent 1) was added to the
cartridges. After 10 min, elution was carried out using 3 mL of the
elution solvent 1 and 3 mL of CHL/IPA 95:5 v/v (elution solvent 2).
Both fractions were collected in the same vial. The combined
eluates were then evaporated at 40°C under a gentle stream of N2.
The dry residues were reconstituted in 120 μL of methanol/water
(30:70 v/v) and injected into the LC-MS system.
Quantification
Calibrators were prepared in human serum provided by Tennessee
Blood Services (Memphis, TN, USA). Each lot was tested before
preparing the calibrators, to ensure that no traces of the target
analytes were detected. An aqueous stock solution containing all
target substances was diluted in serum to obtain 8 calibrator levels.
The calibration ranges were different for digoxin and digitoxin; DG,
DGbis, DGmono, DGenin, H2DG, AcDG and MetDG were measured
between 0.2 and 8 ng/mL and DT, DTbis, DTmono, DTenin,
deslanoside and lanatoside were measured between 2.0 and
80 ng/mL. The following deuterated substances were used as internal
standards: DG-d3 (1.0 ng/mL; used for DG, H2DG, AcDG and MetDG),
DGbis-d3 (0.85 ng/mL), DGmono-d3 (0.85 ng/mL), DGenin-d3
(1.6 ng/mL), DT-d3 (9.1 ng/mL; used for DT, deslanoside and
lanatoside), DTbis-d3 (6.6 ng/mL), DTmono-d3 (7.5 ng/mL) and
DTenin-d3 (7.7 ng/mL). All compounds were quantified by multi-
ple reaction monitoring (MRM) except for DTenin, which was
monitored in selected ion monitoring (SIM mode). Calibration
curves were constructed using analyte/internal standard peak
area ratios.
Instrumentation
The chromatographic system consisted of Dionex (Germering,
Germany) U3000 binary pump, column oven and autosampler.
The analytes were separated on a Phenomenex (Aschaffenburg,
Germany) Kinetex PFP column (2.6 μm, 150×3.0 mm, 100 Å). The
mobile phase was water/70 μmol/L lithium formate/0.1% formic
acid (eluent A) and methanol/water (95:5 v/v)/70 μmol/L lithium
formate/0.1% formic acid (eluent B). Gradient elution was
performed at 300 μL/min and 40 °C. The gradient started with
50% B, increased to 80% B in 9 min and then to 100% B in 3 min.
The final solvent composition was maintained for 2 min, before
reconditioning the column at the initial solvent composition for
3 min; the total run time was 17 min. The mass spectrometer
was a Thermo Scientific (Bremen, Germany) TSQ Vantage triple
quadrupole equipped with a heated electrospray ionization
source (HESI). The sprayer voltage was 3500 V; capillary temper-
ature, 320 °C; vaporizer temperature, 350°C. Nitrogen was used
as sheath gas (30 psi), and auxiliary gas (10 psi). Collision cell
pressure (Argon) was 1.5 mTorr. Multiple reaction monitoring
(MRM) transitions, optimized collision energies (CE) and S-Lens
HF amplitudes for each transition are summarized in Table S1
(Supporting Information). To increase mass spectral acquisition
speed and number of measured data points across each peak, the
chromatographic run was divided into five segments. The first
segment (0–5.5 min) contained DGenin, DGenin-d3, DG-mono
and DG-mono-d3, using a declustering potential (DCV) of 16 V.
During the second segment (5.5 - 7 min), transitions for DG-bis,
DG-bis-d3 and deslanoside were monitored. The third segment
(7–8.6 min) was divided into 2 scan events, one dedicated to DG,
DG-d3, H2DG and lanatoside and the other to DTenin, DTenin-d3
with DCV of 20 V. DT-mono, DT-mono-d3, MetDG and AcDG
were measured in the fourth segment (8.6–9.8 min), and
DT-bis, DT-bis-d3, DT and DT-d3 in the final event (9.8–17 min).
During the final two min, the polarity was switched to negative
mode, to avoid charging effects in the mass spectrometer. The first
3 and last 4 min of each run were directed into the waste to avoid
contamination of the source by salts and residues of matrix compo-
nents contained in the sample extracts.
Method validation
System suitability test
Both sensitivity of the system and retention time of analytes were
checked in the system suitability test prior to any measurement.
For this test, a methanol solution of all analytes at the concentration
of the lowest calibrator (0.2 ng/mL for digoxin and metabolites and
2 ng/mL for digitoxin andmetabolites) was injected into the LC-MS
system. The segments of the chromatographic run were adapted to
the retention times of the analytes to make sure that peaks were
not truncated. Signal-to-noise ratios of analytes were expected to
be above 10:1 to ensure sufficient sensitivity of the system.
Accuracy, precision
For determination of accuracy and precision, four concentration
levels were used. Accuracywas determined by comparing calculated
and theoretical concentrations using three replicates. For intra-assay
precision, six replicates were processed and analyzed in duplicate.
The coefficient of variation (CV) was calculated for the mean of all
six preparations using the averaged values of both injections. For
inter-assay precision, the same experiment was repeated on a differ-
ent day. Samples were analyzed using a HPLC column with different
batch number and CVwas determined using all twelve preparations.
The concentrations of fortified serum samples for the determination
of precision and accuracy are shown in Table 1.
Ion suppression, matrix effects
To ensure that matrix components were not interfering with quan-
tification of the target substances, an ion suppression experiment
using post-column infusion was carried out according to Bonfiglio
et al.[37] and the extent of matrix effects was investigated according
to Matuszewski et al.[38] For this, three samples were prepared: a
spiked serum sample, a blank serum sample that was spiked post-
extraction and a reference solution in methanol containing all
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analytes. The concentration was equivalent to the medium
concentration level (Table 1). Additionally, possible interferences
from glycerophosphocholines (GPChos) were assessed by in-source
multiple reaction monitoring (IS-MRM).[39] Two common product
ions for GPCho’s (triethylammonium-ethyl phosphate (m/z 184)
and trimethylammoniumethylate (m/z 104) were monitored over
the entire chromatographic run time at high declustering voltage
(40 V) to induce in-source fragmentation. A possible transfer of this
method to different matrices such as plasma collected in lithium-
heparin or EDTA tubes was also investigated; spiked serum samples
were sequentially diluted using two plasma pools and theoretical
values were compared to measured concentrations.
Specificity, transfer to other matrices
Specificity of the method was verified by analyzing analyte-free
serum. Possible transfer of the method to plasma samples was
assessed using the low concentration level. Two aliquots of serum
were diluted 1:3, 1:1 and 3:1 with a plasma-pool collected in EDTA
and another collected in lithium heparin tubes. The original sample
and the three dilutions in each plasma-pool were analyzed and
plotted against their theoretical concentration. Linear regression
was performed for both matrices; attention was paid to calculated
slopes and coefficients of regression.
Linearity, sensitivity
For assessment of linearity, the calibration range was extended
down to 80% of the lowest and up to 120% of the highest
calibrator. The coefficient of regression R was desired to be higher
than 0.99 for sufficient linearity. The lower limits of quantification
(LOQ) and detection (LOD) were determined by sequential dilution
and measurement of the lowest calibrator level. The LOQ was
determined as the concentration with signal-to-noise ratio larger
than 10; LOD was defined as the concentration with signal-to-noise
ratio >3.
Stability
Stability of spiked samples at -20°C was investigated as well as
stability of processed extracts in the thermostatted autosampler
at 2-8°C. For these experiments, fortified serum samples were
measured immediately after preparation, after 2 d, 2 and 12 wk.
Processed serum samples were left in the autosampler for several
days andmeasured repeatedly to determine whether any degrada-
tion of analytes occurred. Also, stability of the deuterated internal
standards was assessed in terms of H/D back exchange.
Application to analysis of patient and spiked samples
To verify the trueness of the method, two different studies were
conducted at two different laboratories. Twenty spiked samples
and 9 anonymized pooled patient samples containing digoxin in
the range from 0.2 to 5 ng/mL, and 8 anonymized pooled patient
samples containing digitoxin in the range from 9 to 75 ng/mL
were analyzed. Aliquots were sent to an external laboratory
(Referenzinstitut für Bioanalytik, RfB) for quantitation using a
certified reference method.
Results and discussion
The objective of this work was the development and validation of
an LC-MS/MS reference assay for accurate quantification of digoxin
(DG) and digitoxin (DT) from human serum, as well as 10 metabo-
lites of these drugs. In addition, two structurally related compounds
that are known to significantly cross-react with DG and DT-specific
immunoassays were included. Because of the low therapeutic
concentration levels of DG and DT, the serum samples were pre-
concentrated using a sample workup protocol comprising protein
precipitation and liquid-liquid extraction (LLE). LC-MS/MS analysis
was then performed in ESI positive mode using lithium adduct ions
of the investigated substances.
Optimization of LC-MS/MS conditions
Optimizing the MS system was initially performed using methanol
stock solutions of the analytes, by infusing solutions into the HPLC
flow. In these experiments, it was observed that the cardiac
glycosides generated both [M+H]+ and [M+Na]+ adduct ions, the
ratio of which strongly depended on experimental conditions. To
favor formation of a single ion species for sensitive multiple
reaction monitoring (MRM) analysis, several monovalent cations
were compared as mobile phase additives and their effect on the
response behavior of the target analytes evaluated. Ammonium,
lithium, sodium and cesium were tested as ionic adducts. The most
intense signals were recorded for the cesium adducts of the inves-
tigated drug substances. Unfortunately, [M+Cs]+ adducts tend to
exclusively eliminate the metal cation under collision-induced
dissociation (CID) conditions,[40,41] thus greatly limiting specificity.
The [M+Cs]+→[Cs]+ transition was therefore not utilized in our
further work. Of the other cations, ammonium exhibited only low
affinity for the analytes. Lithium and sodium ions yielded compara-
ble results; lithium was finally chosen as pairing reagent because of
slightly higher signal intensities of [M+Li]+ over [M+Na]+.
Instrument-specific parameters such as electrospray voltage,
capillary and vaporizer temperatures, as well as auxiliary and sheath
gas pressures were then optimized for each analyte individually for
the highest signal-to-noise ratios (see Experimental), in addition to
MS/MS specific operating settings (Table S1, Supporting Information).
The most labile bonds of cardiac glycosides are the glycosidic
bonds, which break at low collision energies under CID conditions.
Consequently, for DG, DT and their metabolites, the most intense
MRM transition was [M+Li]+→130+, corresponding to formation
Table 1. Concentration levels of spiked serum samples used for deter-
mination of accuracy and precision
Analyte Concentration [ng/mL]
Level XLow Level Low Level Medium Level High
DG 0.23 1.13 4.35 8.85
DG-bis 0.22 1.10 4.23 8.62
DG-mono 0.22 1.09 4.22 8.59
DGenin 0.22 1.12 4.32 8.81
H2DG 0.23 1.13 4.35 8.85
AcDG 0.22 1.10 4.26 8.68
MetDG 0.18 0.89 3.44 7.00
DT 2.30 11.5 44.4 90.4
DT-bis 2.24 11.2 43.2 88.0
DT-mono 2.20 11.0 42.5 86.5
DTenin 2.24 11.2 43.2 88.0
Deslanoside 2.24 11.2 43.2 88.0
Lanatoside 2.24 11.2 43.2 88.0
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of the isolated digitoxose ring. Unfortunately, this transition lacked
specificity and was therefore not used here as molecules
comprising a steroidal skeletal structure with one or several sugar
molecules attached are quite common for a wide range of
compounds. The above MRM transition could therefore potentially
lead to false positive and/or inaccurate results. We chose the more
specific transition [M+Li]+→[M+Li-digitoxose]+, despite its lower
yield. This precursor/product ion combination would still lead to
problems if the investigated compounds coeluted in HPLC or flow
injection experiments because in-source fragmentation could
occur and cause the labile glycosidic bond to break, which would
lead to the formation of metabolites in the ionization source and
thus bias the analysis. Baseline HPLC separation was therefore a
necessity for the assay; in our optimized separation, all compounds
eluted with ~1.5 min spacing between each peak (Figure 2).
Careful optimization of chromatographic conditions was also
important because the m/z of several analytes differed by only 2
u, which led to isotope pattern overlaps. The main isotope of
lithium is [7]Li (92.5% natural abundance), while the second
naturally occurring [6]Li isotope occurs at 7.5% abundance. For
H2DG (M=782 g/mol) and DG-d3 (M=783 g/mol), this effect caused
interferences. In theMRM chromatographic trace of H2DG, a second
peak was recorded corresponding to the [6]Li adduct of DG-d3. In
addition, the MRM trace of DG-d3 exhibited a signal for the
[13]C
isotope peak of H2DG. Adequate chromatography resolution was
therefore crucial to distinguish between signals from target analyte
and isotopic cross-talk (Figure 3).
Unfortunately, DTenin exhibited a very resistant structure under
CID conditions, and remained intact up to high CID energies, when
it eventually and suddenly dissociated into many unspecific
product ions, which limited MRM detection sensitivity. We there-
fore chose the [M+Li]+→[M+Li]+ transition for DTenin, which was,
of course, very unspecific but it eliminated or reduced potentially
coeluting isobaric interferences.
Optimization of sample preparation
A two-stage sample preparation protocol was implemented to
achieve the highest possible detection sensitivity of the assay. First,
protein-precipitation was carried out to release protein-bound
analytes and to remove high-abundant proteins, followed by sepa-
ration of the target analytes from residual matrix components by
liquid-liquid extraction (LLE).
Figure 2. MRM traces of the investigated analytes after HPLC separation of the lowest calibrator level (DG and metabolites, 0.2 ng/mL; DT and
metabolites, 2 ng/mL).
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First, several reagents were evaluated for protein precipitation.
Methanol, a mixture of methanol and ethanol, acetonitrile and a
concentrated zinc sulfate solution (10% w/v) were compared. Since
similar signal-to-noise ratios were obtained for methanol and
ZnSO4 in subsequent LC-MS/MS experiments for the majority of
analytes, the phospholipid content of blank serum extracts precip-
itated withmethanol and ZnSO4 were compared according to Little
et al.[39] The results demonstrated that the ZnSO4 extract contained
significantly lower amounts of phospholipids as compared tometh-
anol extracts (Figure 4); ZnSO4 was therefore chosen for all further
experiments. Protein removal efficiency of ZnSO4 in water or in
organic solvents has been investigated in other studies and
provided also good results for serum and plasma samples.[42,43]
For the second step of the sample preparation, several organic
solvents were tested for LLE of the target analytes: for example,
ethylacetate, heptane, DCM, CHL, methyl-t-butylether (MTBE) and
isopropanol (IPA). Different mixtures of solvents were also
compared to achieve the highest possible recovery of all target
analytes simultaneously. The highest recoveries for all analytes
were obtained for the combination of DCM/IPA 90/10 (v/v) and
CHL/IPA 95/5 (v/v) as extraction solvent.
Manual LLE procedures are generally tedious and time consum-
ing, in particular when several extraction steps are required per
sample, as was the case in our application. We therefore transferred
the protocol to SLE cartridges after the optimal extraction solvent
composition had been established. Concentrations between 27%
and 35% of DG and its metabolites and 8–15% of DT and its
metabolites were recovered in the eluates after the two-step
sample preparation workflow as compared to an aqueous refer-
ence solution. These differences are in accordance with the higher
affinity of DT to serum proteins as compared to DG.
Validation
Accuracy/precision
Calculated recoveries were 83%, 100%, 98%, and 102% for DG and
65%, 100%, 102%, and 97% for DT (for the xlow, low, medium, and
high levels, respectively; see Table 2). Calculated CVs for intra-assay
precision were 9.1%, 7.0%, 4.8%, and 3.4% for DG and 17%, 7.0%,
6.9%, and 6.3% for DT (for xlow, low, medium and high levels,
respectively, Table 6). CVs for inter-assay precision were 19%,
8.8%, 7.0%, and 8.1% for DG and 32%, 7.7%, 7.0%, and 9.7% for
DT (for xlow, low, medium and high concentration levels, respec-
tively; Table 3). Intra- and inter-assay precisionwere not determined
Figure 3. MRM traces of DG, H2DG and DG-d3 at 0.6, 0.6, and 1 ng/mL.
Figure 4. Chromatographic traces ofm/z 184 andm/z 104 for two serum extracts, which were precipitated with MeOH (upper trace) or ZnSO4 (lower trace).
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for deslanoside and lanatoside, since only semi-quantitative analy-
sis was required for these substances.
The lowest level investigated showed a significantly higher bias
than the other samples, both with regards to accuracy and preci-
sion. Since linearity was shown over this concentration range, the
lowest level was maintained as calibrator level, but the quantifica-
tion range was limited to 1.1–8.9 ng/mL for DG and its metabolites
and to 12–90 ng/mL for DT and metabolites.
Linearity/sensitivity
The calibration ranges were different for DG and DT and their respec-
tivemetabolites; they were chosen according to expected concentra-
tion levels in human subjects. Calculated coefficients of regression R
were >0.991 for all investigated compounds, demonstrating good
linearity in the investigated calibration ranges. The determined LOD
and LOQ values for all target analytes are summarized in Table 4.
Stability
It was shown that spiked serum calibrators could be stored for 2
weeks at -20°C; after 13 wk the measured values differed signifi-
cantly (4–20%) from the original concentrations. The stability of
DG in processed samples was shown for 12 d, whereas significant
deviations from the initial value were observed for DT after 2 d.
These values should be considered when analyzing patient sam-
ples. Stability of the deuterated internal standards was investigated
Table 2. Recoveries for DG, DT and their metabolites based on spiked serum samples
Level Analyte XLow (n=3) Low (n=3) Medium (n=3) High (n=3)
Spiked conc.
[ng/mL]
Measured conc.
[ng/mL]
Spiked conc.
[ng/mL]
Measured conc.
[ng/mL]
Spiked conc.
[ng/mL]
Measured conc.
[ng/mL]
Spiked conc.
[ng/mL]
Measured conc.
[ng/mL]
DG 0.23 0.19 (83%) 1.1 1.1 (100%) 4.4 4.3 (98%) 8.9 9.1 (102%)
DGbis 0.22 0.16 (73%) 1.1 1.1 (100%) 4.2 4.2 (100%) 8.6 8.3 (97%)
DGmono 0.22 0.19 (86%) 1.1 1.1 (100%) 4.2 4.0 (95%) 8.6 7.8 (91%)
DGenin 0.22 0.17 (77%) 1.1 1.2 (109%) 4.3 4.2 (98%) 8.8 8.3 (94%)
H2DG 0.23 0.15 (65%) 1.1 1.0 (91%) 4.4 4.9 (111%) 8.9 10 (115%)
AcDG 0.22 0.19 (86%) 1.1 1.1 (100%) 4.3 4.1 (96%) 8.7 9.0 (104%)
MetDG 0.18 0.15 (83%) 0.89 0.87 (97%) 3.4 3.2 (94%) 7.0 7.2 (103%)
DT 2.3 1.5 (65%) 12 12 (100%) 44 45 (102%) 90 87 (97%)
DTbis 2.2 1.8 (82%) 11 12 (109%) 43 45 (105%) 88 87 (99%)
DTmono 2.2 1.8 (82%) 11 11 (100%) 43 41 (95%) 867 85 (98%)
DTenin 2.2 2.1 (95%) 11 11 (100%) 43 40 (93%) 88 84 (95%)
Deslanoside 2.2 2.4 (109%) 11 14 (127%) 43 64 (149%) 88 106 (120%)
Lanatoside 2.2 2.4 (109%) 11 11 (100%) 43 50 (116%) 88 102 (116%)
Table 3. Precision
Level
Analyte
XLow Low Medium High
Intra-assay
(n=6)
Inter-assay
(n=12)
Intra-assay
(n=6)
Inter-assay
(n=12)
Intra-assay
(n=6)
Inter-assay
(n=12)
Intra-assay
(n=6)
Inter-assay
(n=12)
DG 9.1% 19% 7.0% 8.8% 4.8% 7.0% 3.4% 8.1%
DGbis 10% 24% 4.0% 4.7% 3.1% 5.9% 3.5% 8.2%
DGmono 20% 27% 8.1% 5.9% 3.2% 6.4% 5.8% 7.3%
DGenin 4.4% 23% 2.9% 4.8% 2.5% 1.8% 6.6% 4.8%
H2DG 21% 45% 22% 18% 8.1% 8.2% 12% 15%
AcDG 10% 19% 8.6% 25% 12% 13% 3.9% 22%
MetDG 10% 23% 11% 9.4% 13% 11% 3.8% 12%
DT 17% 32% 7.0% 7.0% 6.9% 7.7% 6.3% 9.7%
DTbis 12% 23% 8.4% 9.2% 9.4% 10% 9.4% 13%
DTmono 6.3% 21% 7.7% 12% 7.5% 6.1% 14% 11%
DTenin 3.7% 13% 5.1% 4.3% 3.9% 3.7% 3.1% 3.0%
Table 4. LOD and LOQ
Analyte LOD LOQ
DG 0.08 ng/mL 0.12 ng/mL
DGbis 0.04 ng/mL 0.04 ng/mL
DGmono 0.16 ng/mL 0.20 ng/mL
DGenin 0.20 ng/mL 0.20 ng/mL
H2DG 0.04 ng/mL 0.08 ng/mL
AcDG 0.04 ng/mL 0.04 ng/mL
MetDG 0.03 ng/mL 0.06 ng/mL
DT 0.40 ng/mL 0.40 ng/mL
DTbis 0.40 ng/mL 0.40 ng/mL
DTmono 0.39 ng/mL 0.79 ng/mL
DTenin 1.2 ng/mL 2.0 ng/mL
Deslanosid 0.40 ng/mL 0.40 ng/mL
Lanatosid 0.40 ng/mL 0.40 ng/mL
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by analyzing three blank serum samples with addition of internal
standard solution. If significant H/D back exchange of the deuter-
ated analogues was to occur, we expected signals for the native
substances in the blank serum extracts. No such effect was
observed for any of the deuterated analytes. Calibrators and
samples were analyzed in duplicate and run consecutively, to allow
investigation of the stability of the internal standard by monitoring
possible decreases of peak areas during the entire duration of the
analyses. It was shown that the peak areas of the internal standards
remained constant over the entire sequence.
Specificity, transfer to plasma
Specificity of the method was assessed by measuring a pool of
analyte-free serum in triplicate and verifying that no signal coming
either from the matrix or the internal standard was recorded at the
expected retention time of the analytes. No interference was
obvious for any of the analyzed compounds.
Linear regression of sample dilutions with lithium heparin-
plasma showed slopes of 0.91 and 0.97 for DG and DT, respectively,
whereas the values for their metabolites were between 0.74 and
0.98. Correlation coefficients R varied between 0.963 and 0.999. In
EDTA plasma, slopes were 0.96 and 0.95 for DG and DT, respec-
tively; slopes for their metabolites ranged from 0.74 to 1.03 with
coefficients of variation R between 0.987 and 1.00. Transferability
of the method to plasma for DG and DT was shown, with slightly
better results in EDTA compared to lithium heparin plasma but
the quantification of some metabolites can be biased when
analyzed in a different matrix.
Ion suppression, matrix effects
The influence of the matrix was further investigated by setting up
post-column infusion experiments (see Experimental). The
obtained chromatograms for the target analytes DG and DT are
shown in Figure 5. No detrimental ionization effects were observed
for any of the target substances.
The investigation of matrix effects according to Matuszweski
et al.[38] showed a significant influence of thematrix on quantitation
of the target substances; for DG and its metabolites 43% to 66%
was observed, and 85% to 95% for DT and its metabolites.
Phospholipid analysis of the serum extracts according to Little
et al. showed that residual GPCho’s present in serum extracts eluted
mostly at the end of the chromatogram, after the elution of the
target compound with the highest affinity for the separation
column (DT) and therefore did not bias the analysis of the target
substances. (Chromatograms not shown.)
Application to analysis of patient and spiked samples
The results of two laboratories were compared (see Experimental);
linear regression analysis showed the following coefficients: slope
1.1 for DG and 0.89 for DT, intercept -0.08 for DG and 0.28 for DT
with coefficients of regression R=0.987 in both cases. Considering
the small number of samples, the comparison of both methods
demonstrated good correlation and confirmed the trueness of
our method.
Conclusions
Digoxin and digitoxin are frequently used for treatment of cardiac
dysfunctions and can lead to severe side-effects and possibly death
in case of an overdose. The presented LC-MS/MS assay allowed
simultaneous quantitation of digoxin, digitoxin and several of their
metabolites in human serum. Extensive sample preparation, which
combined protein precipitation and supported liquid extraction,
was needed to achieve the required sensitivity. The method was
fully validated; it showed good results in terms of accuracy,
precision, linearity and sensitivity. The transferability of the method
to EDTA and lithium heparin was shown for the two main analytes
and several of their metabolites. Good correlation with an
established reference method for digoxin and digitoxin was also
demonstrated, for spiked and native samples.
Figure 5. Post-column infusion of DG and DT during analysis of processed matrix blank.
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Immunoassay-based tests, which allow very short analyses times
for quantification of therapeutic drugs, are easily biased by pres-
ence of metabolites or structurally similar compounds. The purpose
of the presented LC-MS/MS assay was the use as single reference
method for an immunologic test for DG and a separate test for
DT. The described LC-MS/MS assay did not achieve the perfor-
mance of a certified reference measurement procedure, mainly re-
lated to higher imprecision. This shortcoming could be improved,
for example by using [13]C-labelled stable isotope standards instead
of the deuterated analogs prepared by H/D exchange here. Sensi-
tivity could be further increased by transferring the assay to a latest
generation MS platform or by increasing sample volumes. In addi-
tion, the assay could be specifically optimized for only the twomain
target substances, DG and DT, and omitting the full metabolite
panel as shown in the present work. The latter would increase the
sensitivity, but would obviously entirely change the target applica-
tion of the assay.
Despite the limitations, the assay presented in this study allowed
for fast and accurate quantification of the target compounds and
provides useful information on metabolite profiles in patient
samples.
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Table S1. MRM transitions, collision energies (in parentheses, CE [V]) and S-Lens potentials 
for the investigated compounds and their corresponding internal standards (IS).  
Compound MRM transition S-Lens IS MRM transition 
DG m/z 787.4 à 657.4, 527.3 (45) 293 DG-d3 m/z 790.4à530.4, 660.4 (45) 
DG-bis m/z 657.3 à 527.3, 379.1 (40) 205 DG-bis-d3 m/z 660.7à 382.0, 530.4 (40) 
DG-mono m/z 527.2 à 379.2, 317.1 (25) 167 DG-mono-d3 m/z 530.4 à 320.1, 381.9 (25) 
DGenin m/z 397.2 à 379.2, 351.2, 317.2 (15) 113 DGenin-d3 m/z 400.1 à 319.9, 382.1 (15) 
H2DG m/z 789.4 à 659.4, 529.3, 371.0 (47) 297 DG-d3 m/z 790.4à530.4, 660.4 (45) 
DT m/z 771.4 à 641.4, 511.3 (45) 273 DT-d3 m/z 774.4à 514.3, 644.4 (45) 
DT-bis m/z 641.3 à 511.3, 363.1 (38) 205 DT-bis-d3 m/z 644.4à514.4, 366.4 (45) 
DT-mono m/z 511.3 à 381.2, 363.2 (34) 165 DT-mono-d3 m/z 514.4à 366.1, 384.1 (34) 
DTenin m/z 381.1 à 381.1 (25) 120 DTenin-d3 m/z 384.1 à 384.1 (25) 
AcDG m/z 829.4 à 657.4, 527.3 (45) 305 DG-d3 m/z 790.4à530.4, 660.4 (45) 
MetDG m/z 801.4 à 657.4, 527.3 (43) 280 DG-d3 m/z 790.4à530.4, 660.4 (45) 
Deslanoside m/z 949.4 à 298.9, 429.0 (60) 292 DT-d3 m/z 774.4à 514.3, 644.4 (45) 
Lanatoside m/z 991.5 à 280.9, 471.1 (60) 295 DT-d3 m/z 774.4à 514.3, 644.4 (45) 
 
 
 
 
 
 
 
69 
  
Publication 5 
 
 
70 
Publication 5 
 
Rapid quantification of digitoxin and its metabolites using 
differential ion mobility spectrometry-tandem mass spectrometry  
 
C. Bylda, R. Thiele, U. Kobold, A. Bujotzek, D.A. Volmer 
Anal. Chem., 2015, 87 (4), 2121-2128 
 
 
  
Reproduced with permission from Analytical Chemistry,   
Copyright 2015 American Chemical Society  
Rapid Quantiﬁcation of Digitoxin and Its Metabolites Using
Diﬀerential Ion Mobility Spectrometry-Tandem Mass Spectrometry
Caroline Bylda,†,‡ Roland Thiele,† Uwe Kobold,† Alexander Bujotzek,† and Dietrich A. Volmer*,‡
†Roche Diagnostics GmbH, Penzberg, Germany
‡Institute of Bioanalytical Chemistry, Saarland University, Saarbrücken, Germany
*S Supporting Information
ABSTRACT: This study focuses on the quantitative analysis of the cardiac glycoside
drug digitoxin and its three main metabolites digitoxigenin-bisdigitoxose, digitoxigenin-
monodigitoxose, and digitoxigenin using electrospray ionization-diﬀerential ion mobility
spectrometry-tandem mass spectrometry (ESI-DMS-MS/MS). Despite large molecular
weight diﬀerences, gas-phase separation of the four compounds in the DMS drift cell was
not possible, even by utilizing additional volatile chemical modiﬁers. Baseline separation
was achieved after adduct formation with alkali metal ions, however, and eﬃciency was
shown to improve with increasing size of the alkali ion, reaching optimum conditions for
the largest cesium ion. Subsequently, an assay was developed for quantiﬁcation of
digitoxin and its metabolites from human serum samples and its analytical performance
assessed in a series of proof-of-concept experiments. The method was applied to spiked
human serum pools with concentration levels between 2 and 80 ng/mL. After a short
reversed-phase chromatographic step for desalting the sample, rapid DMS separation of
the analytes was carried out, resulting in a total run time of less than 1.5 min. The
instrumental method showed good repeatability; the calculated coeﬃcients of variation ranged from 2% to 13%.
Ion mobility spectrometry (IMS) separates ionized analytesbased on their mobilities in an electric ﬁeld in the gas phase.1
The mobility depends on its mass, charge, and shape.2 In
classical IMS, ions are separated in a drift cell ﬁlled with inert
buﬀer gas at atmospheric pressure in a constant low electric
ﬁeld. Ions passing through the buﬀer gas are subjected to a
number of collisions and these processes will be inﬂuenced by
the collision cross sections (CCS) of the analyte ions. Ions of
diﬀerent size and shape are thus separated in the drift tube.
Diﬀerential ion mobility spectrometry (DMS) and ﬁeld
asymmetric ion mobility spectrometry (FAIMS) separate ions
based on changes of ion mobility in alternating electric ﬁelds.3
An asymmetric electric waveform (separation voltage, SV),
comprising a short high voltage (10−30 kV/cm) and a longer
low voltage (<1 kV/cm) component, is applied to the drift
tube. Ions are separated based on their mobility diﬀerences
between high and low ﬁelds. Ions oscillate perpendicularly to
the gas ﬂow and only pass through the drift tube if their net
transversal motion equals zero. Similar to a quadrupole mass
analyzer, ions with a particular mobility can be guided through
the drift tube and reach the detector by applying a compound-
speciﬁc compensation voltage (CV).4 If the compensation
voltage is scanned through a wider voltage range, the
diﬀerential ion mobility spectrum of a sample is obtained,
which ﬁnds its analogy in the full scan mass spectrum of the
quadrupole MS. Keeping SV and CV constant at a voltage
speciﬁc for a certain analyte makes the DMS device act as a
ﬁlter, to increase signal-to-noise (S/N) and speciﬁcity. This is
similar to the selected ion monitoring (SIM) mode of the
quadrupole MS.
Signiﬁcant improvements of DMS separation eﬃciency are
obtained by adding polar chemical modiﬁers to the buﬀer
gas.5−9 These modiﬁers alter the drift behavior of ions as a
result of dynamic clustering/declustering processes that
increase the diﬀerence between high and low ﬁeld drift
velocities. During the low ﬁeld, ions form clusters with modiﬁer
molecules, resulting in larger CCS than “naked” ions and
resulting in slower movement. During the high ﬁeld, clusters
are dissociated and mobilities increase.10,11 Schneider et al.
systematically demonstrated enhancement eﬀects for a wide
range of chemical modiﬁers (e.g., isopropanol, ethyl acetate,
acetonitrile), thus reducing considerably the number of
modiﬁers that have to be tested for a speciﬁc application.5,11
Beneﬁcial eﬀects of diﬀerent modiﬁers have been shown for
small molecules,12 pharmacologically active substances,13 and
chiral molecules, such as amphetamine-type compounds.14
Further improvements have been achieved by implementing
multicomponent modiﬁers, which increased peak capacity and
sensitivity for detection of low molecular weight drugs and
allowed ﬁne-tuning separations in speciﬁc applications.15 Drift
times were also strongly inﬂuenced in ESI-IMS-MS after adding
nitrobenzene as a modiﬁer, which has the ability to form large
clusters with small target ions.16 We have recently shown that
Received: August 25, 2014
Accepted: January 14, 2015
Article
pubs.acs.org/ac
© XXXX American Chemical Society A DOI: 10.1021/ac503187z
Anal. Chem. XXXX, XXX, XXX−XXX
Publication 5
71
CV values in DMS for a wide range of chemically diverse
compounds can be very accurately predicted with use of alcohol
modiﬁers based on readily available descriptors such as proton
aﬃnity and gas phase acidity of the modiﬁer molecules.17
Several studies have successfully demonstrated the applica-
tion of ion mobility spectrometry for quantiﬁcation or structure
elucidation of small molecules in complex biological
samples.3,18−22 Generally, addition of a DMS ﬁlter allows
eliminating chemical interferences and therefore considerably
reduces the chemical noise.23 Sample pretreatment can then be
reduced to a minimum or be completely eliminated, as was
shown by Porta et al., who performed direct analysis of cocaine
and tramadol from post-mortem tissues.24 Hall et al. achieved
quantitation of ﬁve drug metabolites in urine using direct
infusion of extracted samples into a DMS-MS system.25 DMS-
MS has also been shown to be very useful for fast separation of
cocaine and its metabolites from common adulterants.26
Metabolite separation (e.g., propranolol7 or morphine27 and
their glucuronide metabolites) was achieved within milli-
seconds. This is signiﬁcantly faster than common LC-MS
assays, which usually take several minutes for chromatographic
separation and detection.
One major advantage of DMS is its ability to distinguish
isobaric and isomeric compounds.7,28−33 The mobility of ions
can also be inﬂuenced by complex formation prior to DMS.
Several types of cations (alkali ions,34,35 ammonium,36 silver,37
copper,38 transition metals39) have been added to enhance
DMS separation. Depending on the geometry of the formed
complexes, the CCS values of the resulting ion clusters, and
hence their mobilities, are strongly inﬂuenced.
In the present work, we investigated complex formation
reactions for the cardiac glycoside digitoxin (DT) and its three
main metabolites (digitoxin-bisdigitoxosid (DTbis), digitoxin-
monodigitoxosid (DTmono), and digitoxigenin (DTenin))
(Figure 1) using the alkali ions Li+, Na+, K+, Rb+, and Cs+, and
their beneﬁcial eﬀect on speciﬁcity of DMS separation.
Subsequently, we developed a rapid assay for quantitative
analysis of the four compounds from human serum and
assessed its analytical performance in a series of proof-of-
concept experiments.
■ EXPERIMENTAL SECTION
Reagents and Chemicals. Acetonitrile was LC-MS grade
from Biosolve (Valenswaard, Netherlands); acetone, butanol,
cyclohexane, diethyl ether, ethanol, ethyl acetate, and formic
acid were from Merck (Darmstadt, Germany). Isopropanol,
cesium formate, lithium formate, rubidium carbonate, and
sodium formate were from Sigma-Aldrich (Steinheim,
Germany), and digitoxin reference standard was from European
Pharmacopeia Reference Standards (Strasbourg, France).
Metabolites digitoxin-bis- and monodigitoxose were old stock
from Boehringer (Mannheim, Germany); digitoxigenin was
from Sigma-Aldrich. Potassium formate was obtained from
Fluka (Neu-Ulm, Germany). Organic-free water was generated
with a Waters Millipore Milli-Q-Plus puriﬁcation system
(Eschborn, Germany).
Instrumentation. An AB Sciex (Concord, Ontario,
Canada) SelexIon DMS device was used on AB Sciex 5500
QTRAP and 6500 QTRAP quadrupole linear ion trap (QqLIT)
mass spectrometers. Electrospray ionization (ESI) in positive
ion mode was performed with the Turbo-V ESI source of these
instruments at +5.5 kV prior to DMS, with the heat injectors
turned oﬀ. Zero air was used as gas 1 (30 psi) and 2 (10 psi),
nitrogen as curtain gas (18 psi), and helium as collision gas
(medium); DP was set to 80 V, EP to 10 V. The liquid
chromatography system was an Agilent (Waldbronn, Germany)
1290 ultrahigh performance LC equipped with two binary
pumps, Inﬁnity autosampler, and thermostat column compart-
ment. LC desalting was carried out with a Waters (Eschborn,
Germany) XTerra C18 column (2.1 × 50 mm, 3.5 μm). For
selected reaction monitoring (SRM), the following transitions
were chosen: m/z 898 → 133, m/z 767 → 133, m/z 637 →
133, and m/z 507 → 133 for DT, DTbis, DTmono, and
DTenin, respectively, which corresponded to the [M+Cs]+ →
[Cs]+ dissociations. The collision gas pressure was set to
Figure 1. Chemical structures of the target analytes.
Analytical Chemistry Article
DOI: 10.1021/ac503187z
Anal. Chem. XXXX, XXX, XXX−XXX
B
Publication 5
72
“medium” and optimized collision energies were 29, 27, 27, and
21 V for DT, DTbis, DTmono, and DTenin, respectively.
DMS Optimization. For qualitative analyses, standard
solutions of the analytes at 3 μg/mL in methanol:water
(50:50 v/v + 0.1% formic acid) were used. Modiﬁers for DMS
separation were water, cyclohexane, diethyl ether, ethyl acetate,
acetonitrile, methanol, ethanol, 2-propanol, and 1-butanol at
1.5%. For DMS of analyte/cation adducts, the following
monovalent cation salts were added to the standard solutions:
Li-formate, Na-formate, K-carbonate, Rb-formate, and Cs-
formate at 1 mmol/L. The DMS temperature was set to
“medium” (225 °C). Separation improved at high separation
voltages (SV = 3.5−4 kV); as the highest setting of 4 kV gave
electrical discharges, SV was reduced to 3.8 kV. Separation was
further improved by turning DMS resolution enhancement on,
which introduced a countercurrent gas ﬂow to increase collision
rate and accentuate diﬀerences of ion mobilities. As this
parameter also caused signal loss at higher values, it was set to
“medium” (25 L/h). The DMS oﬀset was adjusted to −3 V.
Quantitative DMS-MS/MS Analysis. For quantitative
analysis, spiked human serum samples containing the four
DT substances were analyzed. The concentrations of the serum
calibrators were 2, 4, 6, 8, 20, 60, and 80 ng/mL for all analyzed
substances. Initially, serum samples were precipitated with
methanol. In further experiments, a combination of protein
precipitation with methanol and liquid/liquid extraction with
dichloromethane and chloroform was performed. Serum
extracts were injected into the LC system for desalting using
an isocratic mobile phase (methanol:water 80/20 + 0.1 mmol/
L cesium formate). The ﬂow rate was 400 μL/min. A 10-μL
sample was injected and analyzed by DMS-MS/MS; each
analysis was performed in duplicate. After the desalting step,
DMS analysis was performed in two ways. First, characteristic
CV values were chosen for each analyte (−3.0, −4.5, −6.8, and
−11.6 V for DT, DTbis, DTmono, and DTenin, respectively),
as additional ﬁlter prior to SRM transitions. Alternatively, DMS
spectra were recorded between −15 and +2 V (using a 0.25 V
step interval). For this setup, the delay between injection of the
sample and start of the CV scan was carefully optimized and set
to 40 s. Total runtime of this assay including the LC desalting
step was 1.3 min.
For determining accuracy, an additional chromatography step
was performed prior to DMS: eluent A (water + 0.1 mmol/L
cesium formate), eluent B (methanol:water + 0.1 mmol/L
cesium formate) using the same LC column. The gradient
started with 40% B, increased to 100% B within 2.5 min, and
was held for 1 min, before reconditioning the column at the
initial solvent composition for 2 min. The total run time was
4.5 min.
■ RESULTS AND DISCUSSION
The goal of this study was the development of an analytical
assay for digitoxin and its three main metabolites from human
serum samples based on rapid gas-phase separation of the
analytes by diﬀerential ion mobility spectrometry-tandem mass
spectrometry (DMS-MS/MS) without preceding liquid chro-
matography.
DMS Separation of Digitoxin and Its Metabolites.
Initially, the electrospray ionization (ESI) conditions of
digitoxin compounds were optimized by infusion experiments.
All compounds exhibited two main species in their ESI mass
spectra; viz., [M + H]+ and [M + Na]+ ions, reﬂecting the
aﬃnity of these compounds for alkali metal ions. To focus the
ion current solely into one species, lithium was initially added
in large excess to the analyte solutions, resulting in exclusive [M
+Li]+ lithiated species; namely, m/z 771 for DT, m/z 641 for
DTbis, m/z 511 for DTmono, and m/z 381 for DTenin.
DMS separation of these lithiated species was performed
next, with the goal of achieving suﬃcient resolving power for
the analytes in the gas phase without compromising detection
sensitivity. In the ﬁrst set of experiments, DMS measurements
were carried out without a gas phase chemical modiﬁer; this
procedure did not provide baseline separation, however (DMS
spectra not shown). Diﬀerent polar chemical modiﬁers were
then evaluated to increase resolution in the DMS spectra.5,40−43
We explored ethyl acetate, acetonitrile, isopropanol (IPA), and
several linear alcohols ranging from methanol to butanol. The
measured compensation voltages (CV) at the peak maxima for
the digitoxin variants using these modiﬁers are summarized in
Table 1. As is evident from the data, acetonitrile and ethyl
acetate did not improve separation eﬃciency as compared to
experiments without modiﬁer. For the alcohols, on the other
hand, resolution increased with increasing length of the alkyl
chain; however, the signal intensities started to drop for higher
alcohols. This eﬀect was likely caused by ion suppression eﬀects
in the DMS cell from proton transfer reactions to the alcohol
modiﬁers, as proton aﬃnities of alcohols increase with chain
length.44 The optimum modiﬁer in our experiments for lithium
adducts was isopropanol, as a compromise between eﬃciency
and detection sensitivity. The data in Table 1 clearly show
though that DMS baseline separation was not achieved for DT
and its metabolites with use of the combination of lithium
adduct ions and isopropanol as chemical modiﬁer.
Eﬀects of Alkali Ions on DMS Migration Behavior. To
further increase the limited resolving power and separation
eﬃciency in the experiments above, alkali metal ions of
increasing size were used as counterions (DT variants exhibited
strong aﬃnity for alkali metal ions as explained above). Alkali
ion adducts have previously been used to modify separations of
other compounds such as diastereomers (using classical
IMS34), disaccharide isomers (using FAIMS36), and ﬂavonoid
diglycoside isomers,37 but no systematic size speciﬁc eﬀects
were reported in these applications.
In our experiments, [M+X]+ adducts with alkali ions were
readily formed by the DT variants with all investigated alkali
metal ions (X = Li+, Na+, K+, Rb+, Cs+). The smaller DTenin
and DTmono species also formed stable [M+X+2·IPA]+ adduct
ions that survived the transport region after the DMS drift cell
and were detected for Li+ and Na+ (with lower intensities for
K+, Rb+, and Cs+), while DT and DTbis were only seen as [M
+X]+ species for all alkali metal ions. The increased stability of
Table 1. Measured CV Values for DT, DTbis, DTmono, and
DTenin Using Diﬀerent Chemical Modiﬁers and Li+ As
Counter Ion
CV [V]
modiﬁer DT DTbis DTmono DTenin
no modiﬁer 5.7 4.3 5.2 6.9
acetonitrile 6.3 6.4 5.0 6.1
ethyl acetate 6.0 6.6 4.8 6.2
methanol 1.1 0.6 −0.9 −3.1
ethanol 0.5 −0.7 −1.8 −3.9
isopropanol −0.2 −0.8 −2.1 −4.7
butanol −0.9 −3.8 −2.8 no signal
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[M+X+2·IPA]+ ions of DTenin and DTmono was probably
due to stronger electrostatic interactions, stabilized by
coordination with solvent molecules.45,46
Because of the signiﬁcant structural and molecular weight
diﬀerences of the four studied analytes (M = 765, 635, 505, and
375 g/mol for DT, DTbis, DTmono, DTenin, respectively,
Figure 1), we originally expected these compounds to exhibit
very diﬀerent transport behaviors during DMS, even in their
native form as protonated molecules (after ESI), without the
need for any cation modiﬁcations. As seen above, this was not
the case, however, and adduct formation with alkali metal ions
was essential (Figure 2). Coordination of molecules with alkali
metal ions can have a signiﬁcant impact on the conformation of
the compound.47 The interactions of alkali ions with the
digitoxin compounds would likely involve coordination to both
the steroid core as well as the ﬂexible carbohydrate chain.
Carbohydrates composed of several sugar rings have been
studied by other groups and have been shown to be very
complex, due to the ﬂexible structure of these substances and
the multiple electronegative sites that coordinate with the
cations.35,48,49 Importantly, computational experiments have to
consider the chemical modiﬁer in DMS, as both absolute
compensation voltage values and separation eﬃciencies were
strongly enhanced when IPA was used in the DMS cell (Figure
3), as often seen when polar modiﬁers are added.5−9 The
mechanisms of interaction of analytes with modiﬁer molecules
Figure 2. Diﬀerential mobility spectra of DT and its metabolites using diﬀerent alkali metal ions and isopropanol as a DMS modiﬁer. Note: Changes
of relative intensities of the analytes were the result of the used ion species for detection; for DTenin and DTmono [M+X+2·IPA]+ ions were
monitored for Li+ and Na+; [M+X]+ was used for the other cations.
Figure 3. Diﬀerential mobility spectra of the analytes DT, DTbis, DTmono, and DTenin using Cs+ adducts with isopropanol as modiﬁer (left) and
without modiﬁer (right).
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are very complex and not always fully understood.13,50 A
computational description of all interactions of the analytes
with the alkali cations and modiﬁer was outside the scope of
this study
Most importantly, adduct formation inﬂuenced DMS
migration behavior of the target analytes signiﬁcantly, as seen
in Table 2 (for comparison purposes, CV values for the target
substances without modiﬁer are summarized in the Supporting
Information, Table S1). There is a clear trend of increased
resolving power with the size of the counterion (Figure 2), with
the highest resolving power obtained for the heaviest cesium
adduct ions. The calculated resolution (Rs) increased from 0.3,
1.0, and 2.2 (for Li+), to 1.1, 2.2, and 5.9 (for Cs+), in the
separation of DT/DTbis, DTbis/DTmono, and DTmono/
DTenin peak pairs, respectively, while eﬃciency remained
similar for all counterions (Table 2). The relative intensities of
the four analytes depended on the monitored ion species.
DTenin and DTmono were detected as [M+X+2·IPA]+ ions
for Li+ and Na+, and as [M+X]+ for the other cations, which
explains diﬀerences of intensity ratios seen for the four
compounds with Li+ and Na+ versus K+, Rb+, and Cs+.
Quantitative DMS-MS/MS Assay for Human Serum
Samples. Using the optimized DMS and ionization parame-
ters, a DMS-LC-MS/MS method was developed to allow
separation of serum samples directly in the DMS cell after a
short chromatographic step. This very rapid LC run was
initially performed only to remove salts and other ionic or
highly polar interferences, as well as to focus the analytes prior
to DMS-MS/MS, giving coelution of the four target analytes
after only 1 min run time.
The actual separations of the four compounds were
conducted in the gas phase of the DMS cell with isopropanol
as gas phase modiﬁer and cesium ions were added to the
mobile phase to enhance resolution and eﬃciency as described
in the previous sections (Figure 3). To improve speciﬁcity of
the assay, compound-speciﬁc transitions for single reaction
monitoring (SRM) were chosen (see the Experimental
Section), corresponding to [M+Cs]+ → [Cs]+ dissociations.
The same SRM transition has been previously used for an LC-
MS/MS reference method for quantitation of digitoxin in
serum51 and showed robust and reproducible results, even
though overall speciﬁcity is limited because of the somewhat
generic product ion. Cs+ adducts generally tend to only lose the
metal cation under collision-induced dissociation (CID)
conditions.46,52
To implement the method for analysis of patient samples,
fortiﬁed human serum samples with concentration levels
between 2 and 80 ng/mL were used for the experiment.
Samples were precipitated with methanol to remove high-
abundant proteins and extracts directly injected into the DMS-
MS/MS system after a short reversed-phase C18 isocratic run.
The speciﬁc CV values for the four analytes (Table 2) were
used as a DMS ﬁlter, to increase speciﬁcity in concert with the
SRM transitions. For method calibration, peak areas were
integrated and plotted against spiked concentration levels. Lack
of sensitivity in the lower concentration range and an isobaric
interference overlapping with DTenin resulted in a slightly
lower regression slope and higher intercept for this analyte (the
corresponding regression curves are shown in the Supporting
Information, Figure S1). Obviously, protein precipitation was
not suﬃcient to remove all interfering compounds from the
serum samples. Therefore, liquid/liquid extraction was addi-
tionally evaluated for cleanup, to see whether DTenin analysis
can be improved, if required. Duplicate analyses were
performed for each sample. In this second method, we chose
to scan the CV voltage during data acquisition instead of using
ﬁxed CV values for each SRM transition. Because of the fast CV
scanning procedure, this alternative data acquisition routine had
little eﬀect on the overall separation time, but slightly aﬀected
repeatability (see below). An example of a diﬀerential ion
mobility spectrum of a serum sample after this sample
preparation procedure is shown in the Supporting Information
(Figure S2). Correlation of peak areas and spiked concentration
levels exhibited linearities similar to the data above but the
intercept in the calibration curve for DTenin was indeed
smaller, indicating that the additional liquid/liquid extraction
can remove the interference if required (see the Supporting
Information, Figure S3). In our subsequent experiments, we
decided to accept the slightly less linear method for DTenin to
avoid the time-consuming additional liquid/liquid extraction
step.
Trueness of the DMS-MS/MS method was investigated by
analyzing three fortiﬁed serum samples containing all analytes
(6, 20, and 40 ng/mL; low, medium, and high, respectively)
and comparing the measured values to results obtained after
adding a liquid chromatography step (see the Experimental
Section). Recovery values for direct DMS-MS/MS versus LC-
DMS-MS/MS are shown in Table 3. Values ranged from 95%
to 117%. The high bias for DTenin at the lowest concentration
was, again, the result of the interference remaining in the extract
Table 2. CV, Resolution (Rs)
a and Separation Eﬃciency
(Peak Width, fwhm)b for DT, DTbis, DTmono, and DTenin
As a Function of Diﬀerent Alkali Counter Ions (Modiﬁer:
Isopropanol)
CV [V]
counter ion DT DTbis DTmono DTenin
Li+ −0.2 −0.8 −2.1 −4.7
Na+ −0.3 −1.0 −2.3 −4.8
K+ −1.4 −2.4 −4.3 −8.0
Rb+ −2.0 −3.3 −5.7 −10.0
Cs+ −2.5 −4.1 −6.8 −11.8
resolution RS for adjacent peak pairs
counter ion DT/DTbis DTbis/DTmono DTmono/DTenin
Li+ 0.3 1.0 2.2
Na+ 0.4 0.9 1.9
K+ 0.6 1.2 2.6
Rb+ 1.0 1.9 5.1
Cs+ 1.1 2.2 5.9
peak width (fwhm) [V]
counter ion DT DTbis DTmono DTenin
Li+ 2.3 2.2 1.8 1.6
Na+ 2.3 2.0 1.9 1.6
K+ 2.3 2.2 1.9 1.6
Rb+ 2.3 2.0 1.9 1.5
Cs+ 2.4 2.0 1.9 1.5
aResolution for gas-phase species in the CV space was calculated
analogous to chromatography peaks: Rs = 2(CV2 − CV1)/(wb2 + wb1),
where CV1 and CV2 and wb1 and wb2 are the compensation voltages of
the peak maxima and peak widths at baseline, respectively, of the two
adjacent peaks. bEﬃciencies expressed as fwhm (full-width-at-half-
maximum) values.
Analytical Chemistry Article
DOI: 10.1021/ac503187z
Anal. Chem. XXXX, XXX, XXX−XXX
E
Publication 5
75
from insuﬃcient cleanup, which was eﬀectively removed by
chromatography prior to DMS.
To determine the inﬂuence of DMS on the intensity of
background chemical noise signals, a blank serum extract was
measured with and without DMS ﬁlter. As a result, background
noise was reduced 25-fold when DMS was included in the MS/
MS assay and 10-fold when it was included in the LC-MS/MS
assay. These results clearly demonstrate the large gain of
speciﬁcity when using diﬀerential ion mobility as part of the
assay.
The lower limit of quantiﬁcation (LLOQ) of the assay was
deﬁned as the lowest concentration of the calibration range (=2
ng/mL), with a required repeatability of 20% RSD or less at
this level. To verify that the assay was capable of quantifying the
analytes at this calibrator level, coeﬃcients of variation were
calculated for all four analytes at the LLOQ for the mean of six
injections. Coeﬃcients of variation calculated for DT, DTbis,
DTmono, and DTenin at 2 ng/mL were 19%, 18%, 12%, and
14%, respectively; however, a chromatographic separation
should be included in the assay if quantiﬁcation of DTenin is
intended at the low level (see explanation above). Lower
concentrations could be readily quantiﬁed for some of the
target substances. The therapeutic range of digitoxin lies
between 10 and 25 ng/mL,53 however; consequently, there was
no need to extend the calibration range to levels below 2 ng/
mL.
Instrumental method repeatability was investigated by
determining coeﬃcients of variation for all analytes at three
concentration levels: 60, 20, and 4 ng/mL. RSD values were
calculated from measuring the mean of six injections of
prepared serum samples for DT, DTbis, DTmono, and
DTenin, respectively. In comparison, RSD values were also
determined for peaks integrated from diﬀerential ion mobility
spectra. The obtained coeﬃcients of variation are summarized
in Table 4, ranging from 6% to 13% in CV scan mode for the
four analytes, and from 2% to 9% using ﬁxed CV values. Since
no internal standard was used for this proof-of-concept analysis,
the imprecision was slightly higher than usually seen in LC-
MS/MS assays of drugs. Nevertheless, these values were
excellent considering the short analysis time of <1.5 min of
complex serum samples. Both ﬁxed CV and CV scan methods
were implemented for analysis of patient samples, showing
slightly better performance with the ﬁxed CV method in terms
of method repeatability. A CV scan oﬀers the advantage of
direct visualization of the DMS separation and can give
information on possible interferences by observing peak
distortions. It is also not aﬀected by possible drifts of optimal
CV values for the target substances. On the other hand, a
careful optimization of the delay time between injection and
start of the CV scan is required. The use of a speciﬁc CV for
each SRM transition allows slightly faster and more sensitive
analyses, but requires regular tuning of the CV values for the
target components, as CV shifts occur during DMS operation
from buildup of contamination in the drift cell.
A number of LC-MS assays have been reported in the
literature, speciﬁcally for digitoxin,51,54 as part of a broader
analyte panel,55−58 or for combinations with its metabo-
lites.59,60 Several of these assays have achieved better precision
and sensitivity than those obtained here, as a result of more
extensive sample preparation and carefully optimized chroma-
tographic separation. As well, a speed-optimized UHPLC
method, in particular using parallel columns, might achieve
similar throughput rates. The presented DMS-MS/MS
technique does not intend to replace these LC-MS/MS assays,
but rather oﬀers an easy, fast, and reliable alternative in cases
where the performance of a reference method is not needed.
■ CONCLUSIONS
This work has presented diﬀerential ion mobility-mass
spectrometry separation of the cardiac glycoside drug digitoxin
and its main metabolites digitoxigenin-bisdigitoxoside, digitox-
igenin-monodigitoxoside, and digitoxigenin. Gas-phase DMS
separation of the digitoxin compounds was not possible using
the protonated molecules after ionizationeven when using a
chemical modiﬁer to enhance separationdespite the com-
pounds’ large diﬀerences of molecular weight. We have shown
that adduct formation with alkali metal ions had signiﬁcant
impact on the transport behavior and resolution in the DMS
cell, however, readily allowing separation of the digitoxin
compounds. Optimum conditions were achieved with use of
cesium ions and isopropanol as clustering modiﬁer. In a series
of proof-of-concept experiments, the analytical performance
was assessed in terms of linearity, sensitivity, accuracy, and
instrument method repeatability of the method for serum
samples. It was shown that direct DMS/MS-MS analysis of
complex biological samples was readily possible if a sample
preparation step was included in the workﬂow, similar to
comparable chromatography assays. The use of isotope internal
standards for the drugs will undoubtedly improve precision of
this assay further and will be implemented in the future.
Most recently published studies on diﬀerential ion mobility
spectrometry have focused on separation of isobars and
isomers, which are often diﬃcult to analyze by mass
spectrometry and often coelute in liquid or gas chromato-
graphic methods. As shown in this study, DMS can also be used
Table 3. Trueness of the Method Expressed As Recovery of
the Direct DMS-MS/MS Method As Compared to the LC-
DMS-MS/MS Method
recovery [%]
analyte low medium high
DT 111 95 99
DTbis 100 107 103
DTmono 104 117 99
DTenin 56a 102 110
aHigher bias caused by interference that remained in the extract from
insuﬃcient cleanup.
Table 4. Coeﬃcients of Variation for DT, DTbis, DTmono,
and DTenin at Three Concentration Levels: High, Medium,
and Low
coeﬃcient of variation (n = 6) [%] (CV scan)
analyte low medium high
DT 8 12 8
DTbis 7 10 13
DTmono 9 11 13
DTenin 6 6 11
coeﬃcient of variation (n = 6) [%] (ﬁxed CV values)
analyte low medium high
DT 6 8 4
DTbis 7 6 6
DTmono 4 8 3
DTenin 2 9 3
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on its own for separation of mixtures. A similar approach would
probably work well to replace ballistic chromatography (e.g.,
TurboFlow or RapidFire), or for direct ionization techniques
that do not allow separation, such as matrix-assisted laser
desorption/ionization (MALDI) or desorption electrospray
ionization (DESI), or in many other areas such as drugs of
abuse testing (DAT) or therapeutic drug monitoring (TDM).
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